<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Biol Interact</journal-id><journal-id journal-id-type="iso-abbrev">Chem Biol Interact</journal-id><journal-title-group><journal-title>Chemico-Biological Interactions</journal-title></journal-title-group><issn pub-type="ppub">0009-2797</issn><issn pub-type="epub">1872-7786</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8008820</article-id><article-id pub-id-type="pii">S0009-2797(21)00085-5</article-id><article-id pub-id-type="doi">10.1016/j.cbi.2021.109449</article-id><article-id pub-id-type="publisher-id">109449</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Role of phytoconstituents in the management of COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Das</surname><given-names>Amiya</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Pandita</surname><given-names>Deepti</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Jain</surname><given-names>Gaurav Kumar</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Agarwal</surname><given-names>Pallavi</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Grewal</surname><given-names>Ajmer Singh</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Khar</surname><given-names>Roop K.</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Lather</surname><given-names>Viney</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Amity Institute of Molecular Medicine &#x00026; Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, 201313, India</aff><aff id="aff2"><label>b</label>Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, 110017, India</aff><aff id="aff3"><label>c</label>Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India</aff><aff id="aff4"><label>d</label>BS Anangpuria Institute of Pharmacy, Faridabad, Haryana, India</aff><aff id="aff5"><label>e</label>Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida, 201313, India</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, 110017, India</corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author. Amity Institute of Pharmacy, Amity University, Sector-125, Noida, 201313, India.</corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>3</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>25</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2021</year></pub-date><volume>341</volume><fpage>109449</fpage><lpage>109449</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2020</year></date><date date-type="rev-recd"><day>7</day><month>3</month><year>2021</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>COVID-19, a severe global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged as one of the most threatening transmissible disease. As a great threat to global public health, the development of treatment options has become vital, and a rush to find a cure has mobilized researchers globally from all areas.</p></sec><sec><title>Scope and approach</title><p>This review focuses on deciphering the potential of different secondary metabolites from medicinal plants as therapeutic options either as inhibitors of therapeutic targets of SARS-CoV-2 or as blockers of viral particles entry through host cell receptors. The use of medicinal plants containing specific phytomoieties could be seen in providing a safer and long-term solution for the population with lesser side effects.</p><p><italic>Key Findings and Conclusions</italic>: Considering the high cost and time-consuming drug discovery process, therapeutic repositioning of existing drugs was explored as treatment option in COVID-19, however several molecules have been retracted as therapeutics either due to no positive outcomes or the severe side effects. These effects call for exploring the alternate treatment options which are therapeutically effective as well as safe. Keeping this in mind, phytopharmaceuticals derived from medicinal plants could be explored as important resources in the development of COVID-19 treatment, as their role in the past for treatment of viral diseases like HIV, MERS-CoV, and influenza has been well reported. Considering this fact, different phytoconstituents such as flavonoids, alkaloids, tannins and glycosides etc. Possessing antiviral properties against coronaviruses and possessing potential against SARS-CoV-2 have been reviewed in the present work.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="ga1_lrg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>ACE-2</kwd><kwd>COVID-19</kwd><kwd>COVID-19 main protease</kwd><kwd>nCoV-2019</kwd><kwd>Phytoconstituents</kwd><kwd>TMPRSS2</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0025">The ongoing global COVID-19 pandemic still remains a major challenge for scientific communities since its outbreak in December 2019 and has become one of the major causes of mortality and morbidity in large populations. As of June 19, 2020, the World Health Organization (WHO) reported that 213 countries and territories have been affected from this deadly infectious disease originated from Wuhan, China with 8,585,194 infected and 456,439 death cases confirmed worldwide <xref rid="fig3" ref-type="fig">Fig. 3</xref> [<xref rid="bib1" ref-type="bibr">1</xref>]. COVID-19 has not only affected the global health care system but also hampered the economic growth of the countries along with changes in the normal lifestyle and habits [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>]. COVID-19, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is recognized as a communicable and deadly respiratory illness, which begins with normal common cold symptoms and become adverse with course of time leading to fever, dry cough and shortness of breath [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. Certain morbidity factors such as hypertension, cardiovascular diseases, diabetes mellitus, pollution and age increase the risk of COVID-19 [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>].</p><p id="p0030">Coronavirus was first discovered in animals and birds commonly in bats and cats in mid-1960s and found to spread to human by zoonotic transmission [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. The coronaviruses went unrecognised globally until the SARS-CoV pandemic emerged in 2002&#x02013;03 in Guangdong China, which caused severe acute respiratory syndrome (SARS) infecting more than 8000 people with 800 deaths, followed by Middle east respiratory syndrome (MERS-CoV) which emerged in 2012 in Saudi Arabia infecting nearly 2300 people with 850 deaths [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. At the end of December 2019, a novel coronavirus infected several numbers of people in Wuhan, China. On January 2020, this novel virus was named as 2019&#x02010;nCoV officially by WHO and in the same month, several countries became the victim of this deadly infectious virus [<xref rid="bib12" ref-type="bibr">12</xref>]. Therefore, we can say that coronavirus mediated infections occur periodically in different areas of the world. The 2019 novel coronavirus shows 88% sequence similarity with bat derived SARS-CoV and 50% similarity with MERS-CoV [<xref rid="bib13" ref-type="bibr">13</xref>]. WHO estimated the reproductive number (R<sub>0</sub>) for SARS-CoV-2 between 2 and 2.5 higher than the SARS-CoV which is 1.7&#x02013;1.9 and MERS with &#x0003c;1, thus a higher potential of spreading with mortality rate of COVID-19 is 2.3% which is less than that of SARS (~9.5%) and MERS (34.4%). According to various genomic and in vitro analyses, it is clear that SARS-CoV-2 shares same host cell entry receptor as SARS-CoV, i.e., angiotensin converting enzyme-2 (ACE-2) while MERS-CoV uses dipeptidyl peptidase (DPP4). Similar to earlier SARS-CoV and MERS-CoV, the novel SARS-CoV-2 infects part of lungs and thus causes bilateral peripheral pneumonia with multiple organ failures and thus has been declared more contagious than earlier SARS and alveolar MERS [<xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>]. <xref rid="tbl1" ref-type="table">Table 1</xref>
includes the comparative data between SARS-CoV, MERS-CoV and SARS-CoV-2 in terms of their origin, host, transmission, symptoms, incubation period, recovery, etc.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Comparative data of SARS-CoV, MERS-CoV and SARS-CoV-2 [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>].</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>SARS-CoV</th><th>MERS-CoV</th><th>SARS-CoV-2</th></tr></thead><tbody><tr><td align="left"><bold>Origin</bold></td><td align="left">Southern China</td><td align="left">Saudi Arabia</td><td align="left">Wuhan, China</td></tr><tr><td align="left"><bold>Host</bold></td><td align="left">Palm civets</td><td align="left">Camel</td><td align="left">Not known</td></tr><tr><td align="left"><bold>Transmission</bold></td><td align="left">Through close contacts between human to human</td><td align="left">Touching infected camels or consuming their milk or meat</td><td align="left">Human to human transmission through close contacts</td></tr><tr><td align="left"><bold>Symptoms (major)</bold></td><td align="left">Fever, dry cough, headache, difficulty in breathing, muscle aches, loss of appetite, diarrhoea</td><td align="left">Fever, chills, diarrhoea, nausea, vomiting, sneezing, congestion, sore throat</td><td align="left">Fever, fatigue, cough, shortness of breath</td></tr><tr><td align="left"><bold>Incubation Period</bold></td><td align="left">2&#x02013;7 days</td><td align="left">5&#x02013;6 days</td><td align="left">2&#x02013;14 days</td></tr><tr><td align="left"><bold>Recovery</bold></td><td align="left">5&#x02013;6 weeks</td><td align="left">6&#x02013;7 weeks</td><td align="left">2&#x02013;8 weeks</td></tr><tr><td align="left"><bold>Treatment</bold></td><td align="left">No vaccines available, antiviral medicines</td><td align="left">No vaccines available, only drugs for symptoms are available</td><td align="left">No vaccines available, only existing drugs are in use for symptoms</td></tr><tr><td align="left"><bold>Countries effected</bold></td><td align="left">29</td><td align="left">26</td><td align="left">&#x0003e;140</td></tr><tr><td align="left"><bold>Fatality Rate</bold></td><td align="left">9.5%</td><td align="left">34.4%</td><td align="left">2.3%</td></tr></tbody></table></table-wrap></p><sec id="sec1.1"><label>1.1</label><title>Family of coronaviruses</title><p id="p0035">According to International Committee on Taxonomy of Viruses, coronaviruses come under subfamily of Coronavirinae from the family Coronaviridae and order Nidovirales (<xref rid="fig1" ref-type="fig">Fig. 1</xref>
) [<xref rid="bib19" ref-type="bibr">19</xref>]. The Coronavirinae subfamily is further divided into four genera, i.e., alpha-coronavirus, beta-coronavirus, gamma-coronavirus, and delta-coronavirus [<xref rid="bib20" ref-type="bibr">20</xref>]. First two infect only mammals and rest infect birds and in some case mammals too. The alpha-coronaviruses include human coronavirus NL63 (HCoV-NL63), porcine transmissible gastroenteritis coronavirus (TGEV), PEDV, and porcine respiratory coronavirus (PRCV), whereas the beta-coronaviruses include SARS-CoV, MERS-CoV, bat coronavirus HKU4, mouse hepatitis coronavirus (MHV), bovine coronavirus (BCoV), and human coronavirus OC43. The gamma-and delta-coronaviruses include avian infectious bronchitis coronavirus (IBV) and porcine delta-coronavirus (PdCV), respectively [<xref rid="bib21" ref-type="bibr">21</xref>]. The alpha-coronaviruses and beta-coronaviruses result into pulmonary illness in humans and cholera infantum in animals [<xref rid="bib22" ref-type="bibr">22</xref>]. MERS-CoVs are deadly pathogenic viruses causing serious respiratory problem in humans, while other viruses like SARS-CoV and HCoV- NL63, HCoV-229E, HCoV-OC43 and HKU1 do not result into critical conditions compared with the earlier. Domestic animals are the sources for transmission of these viruses from natural host to humans [<xref rid="bib23" ref-type="bibr">23</xref>]. Data collected from various databases show that all the human coronaviruses originated from animals such as SARS-CoV, MERS-CoV, HCoV-NL63 and HCoV-229E originated from bats [<xref rid="bib24" ref-type="bibr">24</xref>]. These studies concluded that bats are mainly responsible for transmission of these. SARS-CoV-2 also has been found to be originated from bats and further spread to human by zoonotic transmission according to reports published [<xref rid="bib25" ref-type="bibr">25</xref>].<fig id="fig1"><label>Fig. 1</label><caption><p>Family of coronaviruses.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0040">The SARS-CoV-2 is a single stranded, enveloped, large positive sense RNA virus with a size of nearly 125&#x000a0;nm and genome size of 27&#x02013;32&#x000a0;kb [<xref rid="bib17" ref-type="bibr">17</xref>]. The virus contains four structural proteins i.e., envelope protein (E), membrane protein (M), spike protein (S) and nucleocapsid protein (N) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>
). Viral genome is packed within nucleocapsid (N) with a shell of envelope outside [<xref rid="bib26" ref-type="bibr">26</xref>]. This envelope is associated with other three structural proteins (M, S, and E) having different functions; the membrane protein is a transmembrane glycoprotein which helps the virus in developing capsid and structure assembly whereas envelope protein is involved in virus packaging and spike protein helps entry into host cells [<xref rid="bib27" ref-type="bibr">27</xref>]. The spikes are responsible for the formation of large protrusion and thus gives them the shape of crown and hence the name corona meaning crown in Latin [<xref rid="bib28" ref-type="bibr">28</xref>].<fig id="fig2"><label>Fig. 2</label><caption><p>Schematic diagram of SARS-CoV-2 structure. Reproduced from Ref. [<xref rid="bib29" ref-type="bibr">29</xref>] with permission from Elsevier.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0045">Currently there is no specific treatment for this deadly infectious disease except quarantine and symptomatic treatment protocol for disease management [<xref rid="bib29" ref-type="bibr">29</xref>]. As it is clear from different reports that the sequence homology of SARS-CoV and SARS-CoV-2 is nearly similar but the transmission efficiencies are different which are probably due to changes in the nucleotide sequences in spike protein (S) and receptor binding domain [<xref rid="bib30" ref-type="bibr">30</xref>]. Medical practitioners are using existing drugs for controlling the symptoms and a community of researchers globally are involved in developing new drug modalities and vaccines since past 8 months, however no success has been met so far and it may still take months to years in developing the same [<xref rid="bib31" ref-type="bibr">31</xref>]. Considering the high virulence of SARS-CoV-2, it is imperative to develop new preventive or therapeutic agents at the earliest to control the current pandemic situation. Bioactive molecules from plants have served as invaluable sources of different therapeutic drugs and are being used in the treatment of various diseases around the world. Medicinal plants are also being explored in management of COVID-19 pandemic in two ways, i.e., either as immunomodulators or viral target inhibitors based on their established roles in managing other viral diseases. The secondary metabolites and other chemical compounds from plants could prove as promising therapeutic agents as antiviral either by inhibiting the viral replication or viral cell entry and/or otherwise treating the underlying infection caused by SARS-CoV-2 and thus could prove a safer and innovative treatment for this viral infectious disease [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>].</p><p id="p0050">This review has thus been planned to list the potential phytomoieties and their plant sources which can be used as inhibitor molecules targeting either the host cell or SARS-CoV-2 therapeutic receptors in providing a safer and long-term solution for the population with lesser side effects.</p></sec><sec id="sec1.2"><label>1.2</label><title>Coronavirus infection mechanism</title><p id="p0055">The SARS-CoV-2 share some sequence homology with SARS-CoV but show different transmission potential and infection range [<xref rid="bib36" ref-type="bibr">36</xref>]. The ongoing COVID-19 disease is seen as more treacherous with still no treatment and could be potentially due to certain functional mutations occurring in the SARS-CoV-2. The major differences observed in SARS-CoV-2 are absent 8a, longer 8b and shorter 3b segments and different Nsp-2 and -3 proteins. Along with these, the open reading frames are also different in some places like in orf8 and orf10 [<xref rid="bib17" ref-type="bibr">17</xref>]. The process of infection is totally dependent on the interaction between virus and the host cell and begins when the viral particles get attached to the cell surface receptor of the host cell and it delivers the nucleocapsid inside the target cell membrane. The main function is provided by S-protein in binding and fusion with the host cell membrane. SARS-CoV-2 binds with the same receptor ACE-2 present in respiratory epithelium and alveoli of lungs, as SARS-CoV. Fusion takes place because of gain of conformational changes by the spike protein and the process depends upon two factors i.e., pH acidification and proteolytic activation [<xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>] (<xref rid="fig3" ref-type="fig">Fig. 3</xref>
). The S-protein is homotrimeric with each subunit having two domains S1; the receptor binding domain and S2; the membrane fusion domain enabling the virus to enter the host cell. After fusion, the cleavage of fusion protein is the prime event for further process of infection and it is the main characteristic of class I viral fusion proteins [<xref rid="bib40" ref-type="bibr">40</xref>].<fig id="fig3"><label>Fig. 3</label><caption><p>Schematic diagram of coronavirus infection. Reproduced from Ref. [<xref rid="bib12" ref-type="bibr">12</xref>] with permission from Elsevier.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p><p id="p0060">S protein is cleaved by proteases into two domain S1 and S2, of which S2 domain is responsible for entering fusion protein inside the membrane of host cell and ultimately facilitating the entry of virus into the cell [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib36" ref-type="bibr">36</xref>]. Unlike SARS-CoV-2, some coronaviruses like MHV-2 and SARS-CoV do not need cleavage of spike protein for entering purpose, they can directly enter inside the cell with the presence of exogenous proteases and this process is 100&#x02013;1000 fold efficient than the endosomal pathway. Proteases like transmembrane protease/serine family (TMPRSS) and human airway trypsin like protease (HAT) both induce the fusion of SARS-CoV-2 [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>]. Once the fusion occurs and fusion protein enters the host cell, ACE-2 gets cleaved and it is covered by ADAM17 in extra membranal space which convert angiotensin I to angiotensin II, a negative regulator of renin angiotensin pathway and this reduced ACE-2 is responsible for respiratory injury and illness [<xref rid="bib43" ref-type="bibr">43</xref>]. Once viral protein gets translated into the cell, various pathways gets activated and are associated with spreading of infection. An ORF3a protein code for Ca<sup>+2</sup> ion channel and activates transcription of NF-kB pathway by interacting TRAF3. The ORF8b protein activates the inflammasome pathway through NLRP3. All these pathways result in overproduction of cytokines and thus cause respiratory problems. JNK pathway is also activated by ORF3a, ORF3b and ORF7a which is responsible for lung disorders [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. The viral infection can be minimized if the virions do not bind to the cell and this can be done by inactivating the virus. SARS-CoV-2 binds more strongly to the receptor ACE-2 than the SARS-CoV and therefore infection transmission rate and virulence is much higher than the SARS-CoV [<xref rid="bib46" ref-type="bibr">46</xref>]. TMPRSS2 associated with ACE-2 is responsible for spreading the infection at initial stages and thus could be another therapeutic target for the new drug discovery [<xref rid="bib47" ref-type="bibr">47</xref>].</p></sec><sec id="sec1.3"><label>1.3</label><title>Therapeutic targets</title><p id="p0065">Currently there are no approved specific treatments or drugs to treat COVID-19 except the clinical management such as infection prevention, control measures and life supportive care [<xref rid="bib48" ref-type="bibr">48</xref>]. The prevailing conditions of current pandemic such as re-emergence of infection cases, uncontrolled transmission and morbidity associated with the disease are crippling the healthcare systems with grave effects on the global economies and posing a challenging situation for health practitioners and scientists to identify the therapeutic strategies to handle this problem [<xref rid="bib49" ref-type="bibr">49</xref>]. Therapeutic repurposing of existing drugs like anti-malarials, antivirals, and NSAIDs etc., has been used as an effective approach in management of COVID-19 with drugs inhibiting either the different viral receptors/enzymes or the host cell receptors. Identification of drug targets (viral or host cell) remains one of the important criteria for the discovery of new molecules as well as to check the therapeutic efficacy of existing drug molecules [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib50" ref-type="bibr">50</xref>]. The below section briefly enlists the potential therapeutic targets along with the current drugs repurposed towards these targets.</p></sec><sec id="sec1.4"><label>1.4</label><title>Angiotensin converting enzyme-2 (ACE-2)</title><p id="p0070">ACE-2 is the functional receptor of SARS-CoV-2 and is a negative regulator of renin angiotensin system (RAS) [<xref rid="bib51" ref-type="bibr">51</xref>]. The S-proteins of SARS-CoV-2 get attached with ACE-2 receptor of the host cell in a much stronger manner compared to the SARS-CoV thus producing higher pathogenicity [<xref rid="bib52" ref-type="bibr">52</xref>]. Many reports have suggested that ACE-2 could be one of the possible COVID-19 targets as it can block the binding of the virus with the host cell and thus blocking the viral cell entry. Therapeutic options for blocking the viral entry utilizing neutralizing antibodies such as soluble receptor binding domain that could occupy ACE-2 and soluble ACE-2 are envisaged as possible viral trap and thus inactivators of SARS-CoV-2 [<xref rid="bib53" ref-type="bibr">53</xref>]. Despite the initial controversy on use of ACE inhibitors and angiotensin receptor blockers (ARBs) in hypertensive COVID-19 patients, several clinical findings have recommended their continued use during infection treatment as these drugs possess anti-inflammatory activities as well as inhibit platelets aggregation and thus preventing clot formation seen in COVID-19. Besides synthetic products, some natural products such as amentoflavone, chrysanthemin, and biovobin have shown good binding affinity towards ACE-2 [<xref rid="bib54" ref-type="bibr">54</xref>,<xref rid="bib55" ref-type="bibr">55</xref>].</p><p id="p0075">Choroquine (CQ), a well-known anti-malarial drug has been explored for prophylactic and therapeutic treatment in current pandemic due to multiple roles in inhibiting the viral life cycle [<xref rid="bib56" ref-type="bibr">56</xref>]. CQ inhibits the viral infection by increasing the endosomal pH value required for the fusion of virus and host cell. Treatment with CQ has shown improved pulmonary abrasion with healthy outcomes. It is also reported that high dose of CQ will cause cardiac risks and its safety and effectiveness is not investigated till now [<xref rid="bib57" ref-type="bibr">[57]</xref>, <xref rid="bib58" ref-type="bibr">[58]</xref>, <xref rid="bib59" ref-type="bibr">[59]</xref>]. Hydroxychloroquine (HCQ) shares the similar structure and antiviral activity with CQ and was looked upon as a better and safer treatment for COVID-19. Both are responsible for inhibiting the spike protein attachment with ACE-2 receptor in the host cell and also interfere with the glycosylation process of ACE-2 of host cell. CQ and HCQ decreased the cytokine storm, in COVID 19 patients. It disrupts the DNA/RNA interaction and reduces the expression of pro inflammatory genes [<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib61" ref-type="bibr">61</xref>]. However, WHO halted the use of combination of HCQ and lopinavir/ritonavir after their failure to reduce the mortality rate [<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib63" ref-type="bibr">63</xref>].</p></sec><sec id="sec1.5"><label>1.5</label><title>Transmembrane protease serine 2 (TMPRSS2)</title><p id="p0080">Along with ACE-2, TMPRSS2 is also responsible for virus entry into the host cells by activating the viral S-proteins [<xref rid="bib36" ref-type="bibr">36</xref>]. TMPRSS2 cuts the S-glycoprotein into two-part S1 and S2. Both subunits function differently; S1 binds with host cell surface receptor and S2 helps in fusion of host and viral cell. It is pertinent to note that spike protein activity is one of the main reasons for the viral pathogenicity and virulence [<xref rid="bib64" ref-type="bibr">64</xref>]. Various studies have shown that inactivating the TMPRSS2 could facilitate inhibition of the viral infection. Camostat mesylate is an example of FDA approved serine TMPRSS2 inhibitor used in other diseases, and is under clinical trials for COVID-19 and will take several months for clinical validation [<xref rid="bib65" ref-type="bibr">65</xref>].</p></sec><sec id="sec1.6"><label>1.6</label><title>RNA dependent RNA polymerase (RdRp)</title><p id="p0085">Nsp12 or RdRp is the main conserved protein present in coronavirus which is responsible for viral replication and transcription. It is a complex machinery, where Nsp12 binds with nsp7 and nsp8 (cofactors) to produce viral genomic RNA [<xref rid="bib66" ref-type="bibr">66</xref>]. SARS-CoV shares the same structure of Nsp12 with the SARS-CoV-2. It was observed that Nsp12 was the potential drug target with much safer profile and less toxicity for SARS-CoV and MERS-CoV [<xref rid="bib52" ref-type="bibr">52</xref>]. Currently, remdesivir (antiviral drug) that targets RdRp activity is under clinical trial and also been used in severely ill-terminal COVID19 patients [<xref rid="bib67" ref-type="bibr">67</xref>]. Docking-based screening studies have found some natural compounds targeting RdRp including nympholide A, viniferin and theaflavin [<xref rid="bib55" ref-type="bibr">55</xref>,<xref rid="bib68" ref-type="bibr">68</xref>].</p></sec><sec id="sec1.7"><label>1.7</label><title>3CL protease</title><p id="p0090">Main protease Nsp5, is also known as 3C like protease which first auto cleaved from the poly proteins and then thereafter cleaves the nsps at 11 sites, i.e., nsp4-nsp16, an essential step in the mechanism of viral infection [<xref rid="bib69" ref-type="bibr">69</xref>]. This is the main protease hence sometimes called as Mpro and it shares almost 96% homology with SARS-CoV. Difference in structure arises in the dimer interface where polar amino group is replaced with nonpolar groups and hence catalytic activity of dimer increases [<xref rid="bib70" ref-type="bibr">70</xref>]. MPro is responsible for viral replication and transcription and considered as an important therapeutic target for COVID-19 [<xref rid="bib71" ref-type="bibr">71</xref>]. A combination strategy using lopinavir-ritonavir; the protease inhibitors was tested against COVID-19, however no benefits was observed and it was observed to cause several side effects like diarrhoea, nausea, asthenia etc., but in some regions of South Korea, this combination was found to be effective, however the testing was done only in one patient [<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib73" ref-type="bibr">73</xref>]. Thus, clinical study with large cohort of population is needed to establish the importance of this protease as drug target for COVID19.</p></sec><sec id="sec1.8"><label>1.8</label><title>Papain-like proteinase (PLpro)</title><p id="p0095">PLpro is a 213&#x000a0;kDa multidomain polypeptide which cleaves the <italic>N</italic>-terminal region of polyprotein and releases nsp1, nsp2 and nsp3 required for correction of viral replication. Along with having role in viral replication, it has other important functions of stripping ubiquitin, deISGylation from proteins of host cell for viral immune evasion processes [<xref rid="bib74" ref-type="bibr">74</xref>]. It is also considered as a promising therapeutic target that not only inhibits viral replication but also saves other cells from being infected by dysregulation of signalling cascades in the infected cells. There is a list of FDA approved drugs for various other diseases that specifically binds with viral PLpro effectively, as observed by virtual screening, however needs in vitro, <italic>in vivo</italic> and clinical validation to establish their effectiveness and clinical use [<xref rid="bib75" ref-type="bibr">75</xref>,<xref rid="bib76" ref-type="bibr">76</xref>].</p></sec><sec id="sec1.9"><label>1.9</label><title>Cathepsin</title><p id="p0100">Like viral protein processing, cellular machinery of virus is also very important and could be a potential therapeutic target [<xref rid="bib77" ref-type="bibr">77</xref>]. Keeping in view that SARS-CoV-2 shares similar viral entry mechanism with SARS-CoV, hence similarities in their cellular machinery such as endocytic mechanism for entering into cell could been visaged. Cathepsin is the lysosomal protease that has role in cellular protein turnover [<xref rid="bib78" ref-type="bibr">78</xref>]. According to various studies, cathepsin B has important role in life cycles of coronavirus, Nipah virus, Ebola virus, influenza virus etc., and helps the virus to enter into cytoplasm through endosomes by fusing with viral envelope and endosomal membrane [<xref rid="bib79" ref-type="bibr">79</xref>]. The most common pathway of viral internalization is clathrin mediated endocytosis as seen in the life cycles of various viruses including coronavirus [<xref rid="bib80" ref-type="bibr">80</xref>,<xref rid="bib81" ref-type="bibr">81</xref>]. Cathepsin L is also a promising target in coronavirus as proved by different studies, and therefore it could be a beneficial target for inhibiting SARS-CoV-2. Drug chlorpromazine is used to inhibit clathrin mediated endocytosis in Ebola virus and is being tested for SARS-CoV-2 too [<xref rid="bib82" ref-type="bibr">82</xref>]. There are several other drugs available to target cathepsin but so far, all are under clinical trials [<xref rid="bib83" ref-type="bibr">83</xref>].</p><p id="p0105">
<xref rid="tbl2" ref-type="table">Table 2</xref>
summarizes the various repurposed drugs alongwith their SARS-CoV-2 therapeutic targets.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>List of repurposed drugs under clinical trial for COVID-19.</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Drugs</th><th>Type</th><th>Target</th><th>Status</th><th>Refs.</th></tr></thead><tbody><tr><td align="left">Camostat mesylate</td><td align="left">Serine protease inhibitor</td><td align="left">TMPRSS2</td><td align="left">Under phase 1 and 2 of clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Nafamostat mesylate</td><td align="left">Serine protease inhibitor</td><td align="left">TMPRSS2</td><td align="left">Under phase 2 and 3 of clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Chloroquine phosphate</td><td align="left">Antimalarial</td><td align="left">ACE-2</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Hydroxy-chloroquine</td><td align="left">Antimalarial</td><td align="left">Endosome, pH elevation</td><td align="left">Still in Controversy</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Remdesivir</td><td align="left">Antiviral</td><td align="left">RdRp</td><td align="left">Under clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Umifenovir</td><td align="left">Antiviral</td><td align="left">Membrane fusion, clathrin-mediated endocytosis</td><td align="left">Under phase 4 of clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Favipiravir</td><td align="left">Antiviral</td><td align="left">RdRp</td><td align="left">Inconsistent results in clinical trials</td><td align="left">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left">Lopinavir</td><td align="left">Protease inhibitor</td><td align="left">3clpro, plpro</td><td align="left">Inconsistent results in clinical trials</td><td align="left">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left">Ribavirin</td><td align="left">Antiviral</td><td align="left">RdRp</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left">Arbidol</td><td align="left">Antiviral</td><td align="left">ACE2</td><td align="left">Under clinical trials</td><td align="left">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left">Baricitinib</td><td align="left">Rheumatoid arthritis</td><td align="left">JAK kinase</td><td align="left">Under clinical trials</td><td align="left">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left">Ritonavir</td><td align="left">Antiviral</td><td align="left">Protease inhibitor</td><td align="left">Inconsistent results in completed clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">EIDD-2801</td><td align="left">Antiviral</td><td align="left">Viral replication</td><td align="left">Prepared for clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Tociliczumab</td><td align="left">mAb</td><td align="left">IL-6 pathway</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Sarilumab</td><td align="left">mAb</td><td align="left">IL-6 pathway</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Bevacizumab</td><td align="left">mAb</td><td align="left">VEGF pathway</td><td align="left">Under clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Vitamin C</td><td align="left">Dietary supplements</td><td align="left">Boost immunity</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Vitamin D</td><td align="left">Dietary supplements</td><td align="left">Boost immunity</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Azithromycin</td><td align="left">Antibiotic</td><td align="left">mRNA translation</td><td align="left">Under phase 4 of clinical trials</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Corticosteroids</td><td align="left">Corticosteroids</td><td align="left">Dampen pro-inflammatory cytokines and possess antifibrotic property</td><td align="left">Still in controversy</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">Clevudine</td><td align="left">Antiviral</td><td align="left">Blocks DNA supply of virus to nucleus</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Isotretinoin</td><td align="left">Retinoid</td><td align="left">Against PLPro</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Ivermectin and Nitazoxanide</td><td align="left">Antiparasitic</td><td align="left">Inhibit import in alpha/beta receptor</td><td align="left">Under phase 2 and 3 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Deferoxamine</td><td align="left">Chelating agents</td><td align="left">Inhibit IL6 synthesis through decreasing NF-Kb.</td><td align="left">Under phase 1 and 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Dexamethasone</td><td align="left">Steroid</td><td align="left">Anti-inflammatory action</td><td align="left">Under phase 4 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Piclidenoson</td><td align="left">A3 adenosine receptor agonist</td><td align="left">Inhibit cytokine storm</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Tranexamic acid</td><td align="left">Antifibrinolytics</td><td align="left">Inhibit conversion of plasminogen to plasmin</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">BLD-2660</td><td align="left">Antiviral</td><td align="left">Targets IL6</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Sildenafil citrate</td><td align="left">Phospho-diesterase inhibitor</td><td align="left">Dilates blood vessles</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Losartan</td><td align="left">Angiotensin II receptor antagonist</td><td align="left">Targets ACE2</td><td align="left">Under phase 1 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Telmisartan</td><td align="left">Antifibrotic</td><td align="left">Angiotensin receptor blocker</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Atorvastatin</td><td align="left">Statin</td><td align="left">Target NF-kB</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Prazosin</td><td align="left">Alpha-blockers</td><td align="left">Prevent cytokine storm</td><td align="left">Under phase 2 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Chlorpromazine</td><td align="left">Antipsychotics</td><td align="left">Inhibit viral replication</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Lenalidomide</td><td align="left">Antiangiogenic agent</td><td align="left">For multiple myeloma patients</td><td align="left">Under phase 4 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr><tr><td align="left">Ruxolitinib</td><td align="left">Anti-inflammatory</td><td align="left">Targets cytokine storm</td><td align="left">Under phase 3 of clinical trials</td><td align="left">[<xref rid="bib13" ref-type="bibr">13</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="sec1.10"><label>1.10</label><title>Therapeutic potential of phytoconstituents against coronaviruses</title><p id="p0110">During this pervasive situation, world is facing unhealthy circumstances impeding the normal lifestyle. It is very much necessary to develop drugs or vaccine for this current deadly infectious disease at the earliest, but unfortunately there are no FDA approved drugs available in the market and development of new therapeutic moieties and vaccine remains a costly and time-consuming affair with high failure chances too [<xref rid="bib12" ref-type="bibr">12</xref>]. Keeping that in mind it is very crucial to use alternate options to combat the current situation. Medicinal plants offer the most common treatment options since ancient times against various viral diseases because of their safer, cheaper and less toxicity profile [<xref rid="bib84" ref-type="bibr">84</xref>]. The National Health Commission of China suggested traditional Chinese medicine as an alternative defence treatment option [<xref rid="bib85" ref-type="bibr">85</xref>]. From literature studies it was seen that phytoconstituents such as polysaccharides, triterpenes, phenolic acids, alkaloids, proanthocyanidins and anthraquinones etc., possessed anti-viral activity against rabies virus, HIV, Chandipura virus, Japanese Encephalitis Virus, Enterovirus, Influenza A/H1N1 and other influenza viruses, and SARS [<xref rid="bib86" ref-type="bibr">[86]</xref>, <xref rid="bib87" ref-type="bibr">[87]</xref>, <xref rid="bib88" ref-type="bibr">[88]</xref>, <xref rid="bib89" ref-type="bibr">[89]</xref>]. <xref rid="tbl3" ref-type="table">Table 3</xref>
encompasses a list of different phytoconstituents which have shown anti-viral activity against different types of coronaviruses.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Phytoconstituents and their plant sources having antiviral potential against different types of coronaviruses.</p></caption><alt-text id="alttext0045">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Compound (source)</th><th>Structure</th><th>Strain</th><th>Targets</th><th>Refs.</th></tr></thead><tbody><tr><td colspan="5" align="left"><bold>Flavonoids</bold></td></tr><tr><td align="left">Luteolin (<italic>Galla Chinensis</italic>)</td><td align="left"><inline-graphic xlink:href="fx1_lrg.gif"><alt-text id="alttext0050">Image 1</alt-text></inline-graphic></td><td align="left">SARS-CoV BJ01</td><td align="left">Binds with S2 subunit</td><td align="left">[<xref rid="bib90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left">Myricetin</td><td align="left"><inline-graphic xlink:href="fx2_lrg.gif"><alt-text id="alttext0055">Image 2</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibit ATPase activity</td><td align="left">[<xref rid="bib91" ref-type="bibr">91</xref>]</td></tr><tr><td align="left">Procyanidin A2 (<italic>Cinnamomi sp.</italic>)</td><td align="left"><inline-graphic xlink:href="fx3_lrg.gif"><alt-text id="alttext0060">Image 3</alt-text></inline-graphic></td><td align="left">SARS-CoV PUMC01 F5</td><td align="left">Targets clathrin dependent endocytosis pathway</td><td align="left">[<xref rid="bib92" ref-type="bibr">92</xref>]</td></tr><tr><td align="left">Scutellarein (<italic>Scutellaria barbata</italic>)</td><td align="left"><inline-graphic xlink:href="fx4_lrg.gif"><alt-text id="alttext0065">Image 4</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibit ATPase activity</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Amentoflavone (<italic>Torreya nucifera</italic>)</td><td align="left"><inline-graphic xlink:href="fx5_lrg.gif"><alt-text id="alttext0070">Image 5</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets CLPro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Bilobetin (<italic>Torreya nucifera</italic>)</td><td align="left"><inline-graphic xlink:href="fx6_lrg.gif"><alt-text id="alttext0075">Image 6</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets CLPro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Ginkgetin (<italic>Torreya nucifera</italic>)</td><td align="left"><inline-graphic xlink:href="fx7_lrg.gif"><alt-text id="alttext0080">Image 7</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets CLPro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Bavachinin (<italic>Psoralea corylifolia</italic>)</td><td align="left"><inline-graphic xlink:href="fx8_lrg.gif"><alt-text id="alttext0085">Image 8</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets PL Pro</td><td align="left">[<xref rid="bib94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left">Neobavaisoflavone (<italic>Psoralea corylifolia</italic>)</td><td align="left"><inline-graphic xlink:href="fx9_lrg.gif"><alt-text id="alttext0090">Image 9</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets PL Pro</td><td align="left">[<xref rid="bib94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left">Tomentin A (<italic>Paulownia tomentosa</italic>)</td><td align="left"><inline-graphic xlink:href="fx10_lrg.gif"><alt-text id="alttext0095">Image 10</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibits PL Pro</td><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left">Tomentin B (<italic>Paulownia tomentosa</italic>)</td><td align="left"><inline-graphic xlink:href="fx11_lrg.gif"><alt-text id="alttext0100">Image 11</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibits PL Pro</td><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left">Tomentin C (<italic>Paulownia tomentosa</italic>)</td><td align="left"><inline-graphic xlink:href="fx12_lrg.gif"><alt-text id="alttext0105">Image 12</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibits PL Pro</td><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left">Tomentin D (<italic>Paulownia tomentosa</italic>)</td><td align="left"><inline-graphic xlink:href="fx13_lrg.gif"><alt-text id="alttext0110">Image 13</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibits PL Pro</td><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left">Tomentin E (<italic>Paulownia tomentosa</italic>)</td><td align="left"><inline-graphic xlink:href="fx14_lrg.gif"><alt-text id="alttext0115">Image 14</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibits PL Pro</td><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left">Hesperetin</td><td align="left"><inline-graphic xlink:href="fx15_lrg.gif"><alt-text id="alttext0120">Image 15</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib96" ref-type="bibr">96</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Phenolic compounds</bold></td></tr><tr><td align="left">Kazinol F (<italic>Broussonetia papyrifera</italic>)</td><td align="left"><inline-graphic xlink:href="fx16_lrg.gif"><alt-text id="alttext0125">Image 16</alt-text></inline-graphic></td><td align="left">MERS-CoV</td><td align="left">Targets PL pro</td><td align="left">[<xref rid="bib97" ref-type="bibr">97</xref>]</td></tr><tr><td align="left">Broussochalcone A (<italic>Broussonetia papyrifera</italic>)</td><td align="left"><inline-graphic xlink:href="fx17_lrg.gif"><alt-text id="alttext0130">Image 17</alt-text></inline-graphic></td><td align="left">MERS-CoV</td><td align="left">Targets PL pro</td><td align="left">[<xref rid="bib97" ref-type="bibr">97</xref>]</td></tr><tr><td align="left">Caffeic acid (<italic>Sambucus formosana</italic>)</td><td align="left"><inline-graphic xlink:href="fx18_lrg.gif"><alt-text id="alttext0135">Image 18</alt-text></inline-graphic></td><td align="left">HCoV-NL63</td><td align="left">Inhibit cell docking</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Isotheaflavin-3-gallate (<italic>Camellia sinensis</italic>)</td><td align="left"><inline-graphic xlink:href="fx19_lrg.gif"><alt-text id="alttext0140">Image 19</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib98" ref-type="bibr">98</xref>]</td></tr><tr><td align="left">Dieckol (<italic>Ecklonia cava</italic>)</td><td align="left"><inline-graphic xlink:href="fx20_lrg.gif"><alt-text id="alttext0145">Image 20</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left">Terrestrimine (<italic>Tribulus terrestris</italic>)</td><td align="left"><inline-graphic xlink:href="fx21_lrg.gif"><alt-text id="alttext0150">Image 21</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against PL Pro</td><td align="left">[<xref rid="bib100" ref-type="bibr">100</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Xanthones</bold></td></tr><tr><td align="left">Blanco-xanthone (<italic>Calophyllum blancoi</italic>)</td><td align="left"><inline-graphic xlink:href="fx22_lrg.gif"><alt-text id="alttext0155">Image 22</alt-text></inline-graphic></td><td align="left">HCoV 229E</td><td align="left">Against Protease</td><td align="left">[<xref rid="bib101" ref-type="bibr">101</xref>]</td></tr><tr><td align="left">Pyrano-jacareubin (<italic>Calophyllum blancoi</italic>)</td><td align="left"><inline-graphic xlink:href="fx23_lrg.gif"><alt-text id="alttext0160">Image 23</alt-text></inline-graphic></td><td align="left">HCoV 229E</td><td align="left">Against Protease</td><td align="left">[<xref rid="bib101" ref-type="bibr">101</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Anthraquinones</bold></td></tr><tr><td align="left">Emodin (<italic>Rheum officinale</italic>)</td><td align="left"><inline-graphic xlink:href="fx24_lrg.gif"><alt-text id="alttext0165">Image 24</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Inhibit binding of S-protein to ACE2</td><td align="left">[<xref rid="bib102" ref-type="bibr">102</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Coumarins</bold></td></tr><tr><td align="left">Psoralidin (<italic>Cullen corylifolium</italic>)</td><td align="left"><inline-graphic xlink:href="fx25_lrg.gif"><alt-text id="alttext0170">Image 25</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against PL Pro</td><td align="left">[<xref rid="bib94" ref-type="bibr">94</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Tannins</bold></td></tr><tr><td align="left">Tannic acid (<italic>Camellia sinensis</italic>)</td><td align="left"><inline-graphic xlink:href="fx26_lrg.gif"><alt-text id="alttext0175">Image 26</alt-text></inline-graphic></td><td align="left">SARS- CoV1</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib16" ref-type="bibr">16</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Terpenoids</bold></td></tr><tr><td align="left">&#x003b2;-Ocimeni (<italic>Laurus nobilis</italic>)</td><td align="left"><inline-graphic xlink:href="fx27_lrg.gif"><alt-text id="alttext0180">Image 27</alt-text></inline-graphic></td><td align="left">SARS-CoV FFM1</td><td align="left">Inhibit viral replication</td><td align="left">[<xref rid="bib103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left">&#x003b2;-Penene (<italic>Laurus nobilis</italic>)</td><td align="left"><inline-graphic xlink:href="fx28_lrg.gif"><alt-text id="alttext0185">Image 28</alt-text></inline-graphic></td><td align="left">SARS-CoV FFM1</td><td align="left">Inhibit viral replication</td><td align="left">[<xref rid="bib103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left">Tanshinone I (<italic>Salvia miltiorrhiza</italic>)</td><td align="left"><inline-graphic xlink:href="fx29_lrg.gif"><alt-text id="alttext0190">Image 29</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets Protease</td><td align="left">[<xref rid="bib104" ref-type="bibr">104</xref>]</td></tr><tr><td align="left">Tanshinone IIA (<italic>Salvia miltiorrhiza</italic>)</td><td align="left"><inline-graphic xlink:href="fx30_lrg.gif"><alt-text id="alttext0195">Image 30</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets Protease</td><td align="left">[<xref rid="bib104" ref-type="bibr">104</xref>]</td></tr><tr><td align="left">Tanshinone IIB (<italic>Salvia miltiorrhiza</italic>)</td><td align="left"><inline-graphic xlink:href="fx31_lrg.gif"><alt-text id="alttext0200">Image 31</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets Protease</td><td align="left">[<xref rid="bib104" ref-type="bibr">104</xref>]</td></tr><tr><td align="left">Celastrol (<italic>Tripterygium regelii</italic>)</td><td align="left"><inline-graphic xlink:href="fx32_lrg.gif"><alt-text id="alttext0205">Image 32</alt-text></inline-graphic></td><td align="left">SARS-CoV</td><td align="left">Targets protease</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Leukamenin (<italic>Lactuca sativa</italic>)</td><td align="left"><inline-graphic xlink:href="fx33_lrg.gif"><alt-text id="alttext0210">Image 33</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Protease inhibitor</td><td align="left">[<xref rid="bib105" ref-type="bibr">105</xref>]</td></tr><tr><td align="left">Glaucocalyxin (<italic>Lactuca sativa</italic>)</td><td align="left"><inline-graphic xlink:href="fx34_lrg.gif"><alt-text id="alttext0215">Image 34</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Protease inhibitor</td><td align="left">[<xref rid="bib105" ref-type="bibr">105</xref>]</td></tr><tr><td align="left">Pseurata (<italic>Lactuca sativa</italic>)</td><td align="left"><inline-graphic xlink:href="fx35_lrg.gif"><alt-text id="alttext0220">Image 35</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Protease inhibitor</td><td align="left">[<xref rid="bib105" ref-type="bibr">105</xref>]</td></tr><tr><td align="left">Pristimerin (<italic>Celastrus orbiculatus</italic>)</td><td align="left"><inline-graphic xlink:href="fx36_lrg.gif"><alt-text id="alttext0225">Image 36</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Targets Protease</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Tingenone (<italic>Celastrus orbiculatus</italic>)</td><td align="left"><inline-graphic xlink:href="fx37_lrg.gif"><alt-text id="alttext0230">Image 37</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Targets 3CL Pro</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Iguesterin (<italic>Celastrus orbiculatus</italic>)</td><td align="left"><inline-graphic xlink:href="fx38_lrg.gif"><alt-text id="alttext0235">Image 38</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Targets 3CL Pro</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Friedelanol (<italic>Euphorbia neriifolia</italic>)</td><td align="left"><inline-graphic xlink:href="fx39_lrg.gif"><alt-text id="alttext0240">Image 39</alt-text></inline-graphic></td><td align="left">HCoV-229E</td><td align="left">Antiviral activity</td><td align="left">[<xref rid="bib106" ref-type="bibr">106</xref>]</td></tr><tr><td align="left">Friedelin (<italic>Euphorbia neriifolia</italic>)</td><td align="left"><inline-graphic xlink:href="fx40_lrg.gif"><alt-text id="alttext0245">Image 40</alt-text></inline-graphic></td><td align="left">HCoV-229E</td><td align="left">Antiviral activity</td><td align="left">[<xref rid="bib106" ref-type="bibr">106</xref>]</td></tr><tr><td align="left">Epitaraxerol (<italic>Euphorbia neriifolia</italic>)</td><td align="left"><inline-graphic xlink:href="fx41_lrg.gif"><alt-text id="alttext0250">Image 41</alt-text></inline-graphic></td><td align="left">HCoV-229E</td><td align="left">Antiviral activity</td><td align="left">[<xref rid="bib106" ref-type="bibr">106</xref>]</td></tr><tr><td align="left">Tingenone (<italic>Tripterygium regeli</italic>)</td><td align="left"><inline-graphic xlink:href="fx42_lrg.gif"><alt-text id="alttext0255">Image 42</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Iguesterin (<italic>Tripterygium regeli</italic>)</td><td align="left"><inline-graphic xlink:href="fx43_lrg.gif"><alt-text id="alttext0260">Image 43</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Pristimererin (<italic>Tripterygium regeli</italic>)</td><td align="left"><inline-graphic xlink:href="fx44_lrg.gif"><alt-text id="alttext0265">Image 44</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td align="left">Dihydrotanshinone I (<italic>Salvia miltiorrhiza</italic>)</td><td align="left"><inline-graphic xlink:href="fx45_lrg.gif"><alt-text id="alttext0270">Image 45</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3 CL Pro and PL Pro</td><td align="left">[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr><tr><td align="left">Cryptotanshinone (<italic>Salvia miltiorrhiza</italic>)</td><td align="left"><inline-graphic xlink:href="fx46_lrg.gif"><alt-text id="alttext0275">Image 46</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3 CL Pro and PL Pro</td><td align="left">[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Alkaloids</bold></td></tr><tr><td align="left">Tryptanthrin (<italic>Strobilanthes cusia</italic>)</td><td align="left"><inline-graphic xlink:href="fx47_lrg.gif"><alt-text id="alttext0280">Image 47</alt-text></inline-graphic></td><td align="left">HCoV-NL63</td><td align="left">Targets papain like protease</td><td align="left">[<xref rid="bib108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left">Indigodole B (<italic>Strobilanthes cusia</italic>)</td><td align="left"><inline-graphic xlink:href="fx48_lrg.gif"><alt-text id="alttext0285">Image 48</alt-text></inline-graphic></td><td align="left">HCoV-NL63</td><td align="left">Targets papain like protease</td><td align="left">[<xref rid="bib108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left">Tetrandrine (<italic>Stephania tetrandra</italic>)</td><td align="left"><inline-graphic xlink:href="fx49_lrg.gif"><alt-text id="alttext0290">Image 49</alt-text></inline-graphic></td><td align="left">HCoV-OC43</td><td align="left">Inhibit viral replication</td><td align="left">[<xref rid="bib109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left">Fangchinoline (<italic>Stephania tetrandra</italic>)</td><td align="left"><inline-graphic xlink:href="fx50_lrg.gif"><alt-text id="alttext0295">Image 50</alt-text></inline-graphic></td><td align="left">HCoV-OC43</td><td align="left">Inhibit viral replication</td><td align="left">[<xref rid="bib109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left">Cepharanthine (<italic>Stephania tetrandra</italic>)</td><td align="left"><inline-graphic xlink:href="fx51_lrg.gif"><alt-text id="alttext0300">Image 51</alt-text></inline-graphic></td><td align="left">HCoV-OC43</td><td align="left">Inhibit viral replication</td><td align="left">[<xref rid="bib109" ref-type="bibr">109</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Fatty acids</bold></td></tr><tr><td align="left">Isolinoleic acid (<italic>Mucuna pruriens</italic>)</td><td align="left"><inline-graphic xlink:href="fx52_lrg.gif"><alt-text id="alttext0305">Image 52</alt-text></inline-graphic></td><td align="left">SARS-CoV1</td><td align="left">Targets Protease</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Steroidal derivatives</bold></td></tr><tr><td align="left">Saikosaponin B2 (<italic>Bupleurum sp.</italic>)</td><td align="left"><inline-graphic xlink:href="fx53_lrg.gif"><alt-text id="alttext0310">Image 53</alt-text></inline-graphic></td><td align="left">HCoV-229E</td><td align="left">Targets viral replication</td><td align="left">[<xref rid="bib110" ref-type="bibr">110</xref>]</td></tr><tr><td align="left">&#x003b2;-Sitosterol (<italic>Isatis indigotica</italic>)</td><td align="left"><inline-graphic xlink:href="fx54_lrg.gif"><alt-text id="alttext0315">Image 54</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Flavaglines</bold></td></tr><tr><td align="left">Silvestrol (<italic>Algaria sp.</italic>)</td><td align="left"><inline-graphic xlink:href="fx55_lrg.gif"><alt-text id="alttext0320">Image 55</alt-text></inline-graphic></td><td align="left">MERS-CoV</td><td align="left">Targets RNA helicase</td><td align="left">[<xref rid="bib111" ref-type="bibr">111</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Glucosides</bold></td></tr><tr><td align="left">Sinigrin</td><td align="left"><inline-graphic xlink:href="fx56_lrg.gif"><alt-text id="alttext0325">Image 56</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3CL Pro</td><td align="left">[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Chalcones</bold></td></tr><tr><td align="left">Xanthoangelol (<italic>Angelica keiskei</italic>)</td><td align="left"><inline-graphic xlink:href="fx57_lrg.gif"><alt-text id="alttext0330">Image 57</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against 3 CL Pro and PL Pro</td><td align="left">[<xref rid="bib112" ref-type="bibr">112</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Diarylheptanoids</bold></td></tr><tr><td align="left">Hirsutenone (<italic>Alnus japonica</italic>)</td><td align="left"><inline-graphic xlink:href="fx58_lrg.gif"><alt-text id="alttext0335">Image 58</alt-text></inline-graphic></td><td align="left">SARS CoV</td><td align="left">Against PL Pro</td><td align="left">[<xref rid="bib113" ref-type="bibr">113</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Lectins</bold></td></tr><tr><td align="left">Agglutinin (<italic>Urtica dioica</italic>)</td><td align="left">-</td><td align="left">SARS-CoV</td><td align="left">Targets viral replication</td><td align="left">[<xref rid="bib114" ref-type="bibr">114</xref>]</td></tr><tr><td align="left">Griffithsin (<italic>Griffithsia sp.</italic>)</td><td align="left">-</td><td align="left">SARS-CoV</td><td align="left">Against glycoprotein spike</td><td align="left">[<xref rid="bib115" ref-type="bibr">115</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec2"><label>2</label><title>Various phytoconstituents that are being studied for the treatment of COVID-19 fall under the following classification</title><sec id="sec2.1"><label>2.1</label><title>Flavonoids</title><p id="p0115">Flavonoids are polyphenolic compounds present in plants and possess different biological functions [<xref rid="bib116" ref-type="bibr">116</xref>]. Many flavonoids are seen having effective role against viral infections especially at the molecular level for inhibiting the growth of virus [<xref rid="bib117" ref-type="bibr">117</xref>]. Flavonoids block the entry of virus into the cell by blocking the cellular receptors and also interfere with viral replication and translation [<xref rid="bib118" ref-type="bibr">118</xref>]. Considering the important role played by Mpro enzyme in viral replication and translation, it can be used as one of the potential targets for COVID-19. Different virtual screening studies carried against Mpro enzyme have proposed several flavonoids like azithromycin, mangiferin, procyanidin-&#x003b2;-2,7-dimethoxyflavaN-4&#x02032;-O-&#x003b2;-<sc>d</sc>-glucopyranoside, amentoflavone, hidrosmin, diosmin, gallocathechin gallate, elsamitrucin, pectolinaren, quercetin and isoquercetin having high binding affinities and thus could be used to combat the current situation. Along with the Mpro, ACE-2 is also a potential therapeutic target and flavonoids including hesperetin, myricetin, linebacker and caflanone have shown high binding affinity against ACE-2 making them important points of study against SARS-CoV-2 [<xref rid="bib119" ref-type="bibr">119</xref>,<xref rid="bib120" ref-type="bibr">120</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>Alkaloids</title><p id="p0120">Alkaloids are naturally occurring organic compounds containing basic nitrogen atoms [<xref rid="bib121" ref-type="bibr">121</xref>]. Alkaloids were found to have key roles in inhibition of viral replication as it blocks the function of viral DNA polymerase [<xref rid="bib122" ref-type="bibr">122</xref>]. As these plant's secondary metabolites have DNA intercalating properties, they may be effective candidates against viral infection and could lead to development of drug molecules. Resoquine, synthetic derivative of quinine (alkaloid), an antimalarial drug has been found as an effective therapeutic agent against COVID-19 [<xref rid="bib123" ref-type="bibr">123</xref>]. Isoquinoline was effective against spike protein and nucleocapsid protein of SARS-CoV-OC43 in human lung cells suggesting that this could serve as a drug candidate against SARS-CoV-2. Some alkaloids which are having DNA intercalating activity are sanguinarine, quinine, cinchonine, hartmine, chelidonine, coptisine, berberine, palmatin, tetradine etc., and could be used for development of drug molecules [<xref rid="bib124" ref-type="bibr">124</xref>,<xref rid="bib125" ref-type="bibr">125</xref>]. Emetine isolated from ipecacuanha root for induction of vomiting in the poisoning management has been found as effective against COVID-19 [<xref rid="bib126" ref-type="bibr">126</xref>].</p></sec><sec id="sec2.3"><label>2.3</label><title>Phenolics</title><p id="p0125">Phenolics are naturally occurring plant polyphenolic compounds having one or more hydroxyl groups which bind with aromatic hydrocarbon group. They possess the chemical properties where hydroxyl group dissociates under various physiological conditions [<xref rid="bib127" ref-type="bibr">127</xref>]. Phenolic compounds carrying five or more hydroxyl group along with methoxyl group have antiviral properties [<xref rid="bib128" ref-type="bibr">128</xref>]. Plants like <italic>Euphorbia spindens</italic> and <italic>Bombax malabaricium</italic> were tested for anti-HSV and anti-RSV respectively and were effective like ribavirin (antiviral) synthetic drugs [<xref rid="bib129" ref-type="bibr">129</xref>]. Phenols help in inhibiting the fusion of virus to the host cell by binding with the viral protein present in the viral envelope. Since most of the polyphenols are polar molecules and hence cannot be taken up by the host cells and thus may prove as good candidates against COVID-19 [<xref rid="bib123" ref-type="bibr">123</xref>,<xref rid="bib130" ref-type="bibr">130</xref>,<xref rid="bib131" ref-type="bibr">131</xref>].</p></sec><sec id="sec2.4"><label>2.4</label><title>Essential oils</title><p id="p0130">Essential oils are the volatile concentrated hydrophobic liquids extracted from plants. Essential oils are extensive used in phytomedicine and aromatherapy and also in pharmaceuticals. They possess different biological functions like antibacterial, antifungal, antiviral, antioxidant, anti-inflammatory, anticancer etc. [<xref rid="bib132" ref-type="bibr">132</xref>]. Several reports described the effective antiviral activity of essential oils on influenza virus, herpes simplex virus etc. A mixture of essential oil and oleoresins from medicinal plants was also tested for coronavirus, bronchitis virus etc. [<xref rid="bib133" ref-type="bibr">133</xref>]. Essential oil easily interacts with phospholipid bilayer of the cell membrane and it disrupt the viral envelope, thus starting their activity prior to host cell attachment.</p><p id="p0135">Lypophillic essential oils work on membrane viral proteins required for fusion but its activity stops once the virus enters inside the cell [<xref rid="bib134" ref-type="bibr">[134]</xref>, <xref rid="bib135" ref-type="bibr">[135]</xref>, <xref rid="bib136" ref-type="bibr">[136]</xref>, <xref rid="bib137" ref-type="bibr">[137]</xref>]. Recently a team of scientists tested cannabis terpenes for antiviral activity against COVID-19 and the terpenes were found to reduce the severity of SARS virus by interruption with RNA replication proteins thus interfering with viral penetration in healthy cells [<xref rid="bib124" ref-type="bibr">124</xref>]. Various essential oils have proved to be effective against various types of viruses which includes isoborneol, a monoterpenene, having antiviral effect against HSV1. Similarly, eugenol delayed the growth of Herpes virus and also interferes with HSV, while beta-caryophyllene was found to be effective against dengue virus [<xref rid="bib138" ref-type="bibr">138</xref>,<xref rid="bib139" ref-type="bibr">139</xref>]. Vanguard Scientific recently launched an effective hand sanitizer having plant derived terpenes [<xref rid="bib140" ref-type="bibr">140</xref>]. Essential oils thus constitute a major group of phytochemicals which are needed to be investigated thoroughly for the finding of new effective treatment against the COVID-19 severity.</p></sec><sec id="sec2.5"><label>2.5</label><title>Stilbenes</title><p id="p0140">Stilbenes are naturally occurring defensive phenolic compounds found in grapes, berries, bark waste etc., also classified as phytoalexins as they are synthesized by plants in response to UV radiations. Stilbene have many biological functions like antioxidant, anticancer, anti-inflammatory, antileukemia, anti-HIV, anti-Herpes simplex virus, etc. [<xref rid="bib141" ref-type="bibr">141</xref>,<xref rid="bib142" ref-type="bibr">142</xref>]. Different virtual screening studies suggested the use of stilbenes in COVID-19 as they inhibit the complex formed between spike protein and ACE-2 receptor by disrupting the interface of S-ACE-2 complex and thus blocking the entry to the host cell. Stilbenes having high binding affinity to this complex include resveratrol and piceatannol. Some other derivatives of stilbenes like <italic>trans</italic>-resveratrol, pinosylvin, pterostilbene also have antiviral properties but with low binding capacity than mentioned previously [<xref rid="bib143" ref-type="bibr">[143]</xref>, <xref rid="bib144" ref-type="bibr">[144]</xref>, <xref rid="bib145" ref-type="bibr">[145]</xref>]. Resveratrol has been already tested for MERS-CoV and was found effective as it decreases the cell death [<xref rid="bib146" ref-type="bibr">146</xref>]. Based on these studies, it is suggested that stilbenes derivatives, especially resveratrol could be very important drug candidate for COVID-19.</p></sec><sec id="sec2.6"><label>2.6</label><title>Glycosides</title><p id="p0145">Glycosides are simple sugar molecules having different functional groups. Different drugs and poisons extracted from plants are glycosides and thus useful in various treatments [<xref rid="bib147" ref-type="bibr">147</xref>]. Antiviral effects of glycosides have been observed in various studies like the cardiac glycosides were seen effective against both DNA and RNA viruses including cytomegalo virus, herpes simplex virus, influenza virus and coronavirus [<xref rid="bib148" ref-type="bibr">148</xref>]. It targets the cell host protein and thus makes them promising strategy against human viral infections [<xref rid="bib149" ref-type="bibr">149</xref>]. It was already seen that glycosides are effective for influenza virus as it interferes with the virus attachment and disturbs the release of new viruses by inhibiting the hemagglutinin and sialidase enzymes [<xref rid="bib150" ref-type="bibr">150</xref>,<xref rid="bib151" ref-type="bibr">151</xref>]. Iridoid glycosides from <italic>Fructus gardeniae</italic> are very much effective against influenza A as it reduced the cell death by suppressing influenza virus replication [<xref rid="bib152" ref-type="bibr">152</xref>]. According to a recent report, antiviral activity of Ginsenoside Rb1 class of steroid glycosides was tested and found to be effective against SARS-CoV [<xref rid="bib153" ref-type="bibr">153</xref>]. Thus, glycosides derivatives need detailed investigation as drug targets for minimising the current pandemic scenario.</p></sec><sec id="sec2.7"><label>2.7</label><title>Saponins</title><p id="p0150">Saponins are non-ionic detergents which possess antifungal, cytotoxic, antibacterial and antiviral properties [<xref rid="bib154" ref-type="bibr">154</xref>]. Saponins are used in the development of steroidal drugs and thus used in modern medicine [<xref rid="bib155" ref-type="bibr">155</xref>]. Saponins carries antiviral activity as it can interact with viral envelope and capsid protein which results into disruption of viral particles, also it can interact with host cell membrane which inhibit the viral particle attachment to the host cells thus prevent fusion by coating the cell surface which minimizes the spreading of infections. Some study found that <italic>Quilaja saponaria</italic> extract containing triterpenoid saponins having very strong activity in both human and animal's vaccines. This extract was very effective against HIV-1 and -2 [<xref rid="bib156" ref-type="bibr">156</xref>,<xref rid="bib157" ref-type="bibr">157</xref>]. Similarly, triterpene saponin from <italic>Anagallis arvensis</italic> showed antiviral activity against HSV1 and poliovirus 2 [<xref rid="bib158" ref-type="bibr">158</xref>]. Saikosaponins are triterpene saponin glycosides that have been reported having effective antiviral activity against coronavirus HCoV-229E. Saikosaponins interfere with the early stage of viral replication including adsorption and penetration. Some studies demonstrated the antiviral activity of saikosaponins on other viruses like herpes simplex virus, hepatitis B virus and cytomegalovirus and HIV [<xref rid="bib110" ref-type="bibr">110</xref>,<xref rid="bib159" ref-type="bibr">159</xref>]. Thus, this approach of saponins needs attention of scientists for investigation in detail for the development of effective therapeutic candidate against COVID-19.</p></sec><sec id="sec2.8"><label>2.8</label><title>Tannins</title><p id="p0155">Tannins are naturally occurring compounds found in plants, seeds, bark, wood and fruits etc. and possess various biological properties and medical uses. The viral infections lead to the overproduction of free radicals and thus oxidative stress triggering the production of reactive oxygen and nitrogen molecules and tannins extracted from plants are very much effective against oxidative stress [<xref rid="bib160" ref-type="bibr">160</xref>,<xref rid="bib161" ref-type="bibr">161</xref>]. Several studies confirmed the antioxidant effect as a potential therapy against various viral infections [<xref rid="bib162" ref-type="bibr">162</xref>]. Antiviral activity of tannins against various viruses like enterovirus, calicioviruses, rotavirus, HIV, herpes simplex virus, and coronaviruses, etc., has been well established [<xref rid="bib163" ref-type="bibr">163</xref>]. Tannins like pedunculagin, tercatainj and punicalin can binds effectively with SARS-CoV-2 which interferes with viral binding site and destroy the protease enzymes such as His41 and Cys145 and this was studied recently by molecular docking methods [<xref rid="bib164" ref-type="bibr">164</xref>]. A recent study from India suggested the use of tea and haritaki having therapeutic potential against COVID19 as gallotannin present in tea can interfere with 3CLPro protease activity of coronavirus, but yet clinical trials are not done [<xref rid="bib165" ref-type="bibr">165</xref>].</p></sec><sec id="sec2.9"><label>2.9</label><title>Anthraquinones</title><p id="p0160">Anthraquinones are naturally occurring aromatic compounds having wide range of medicinal applications such as in constipation, arthritis, multiple sclerosis, cancer and others and demonstrate low toxicity with high activity [<xref rid="bib166" ref-type="bibr">166</xref>,<xref rid="bib167" ref-type="bibr">167</xref>]. Currently molecular docking studies showed the effect of anthraquinones against SARS-CoV-2. Derivatives such as emodin, aloin A and B, rubiadin, aloe-emodin, pseudohypericin, damnacanthal, and chryosphanic etc., were found as inhibitors of Mpro of SARS-CoV-2 using docking studies. But the detailed <italic>in vivo</italic> and <italic>invitro</italic> studies are required to be done to develop promising drug candidate against COVID19 [<xref rid="bib168" ref-type="bibr">[168]</xref>, <xref rid="bib169" ref-type="bibr">[169]</xref>, <xref rid="bib170" ref-type="bibr">[170]</xref>]. Emodin extracted from <italic>Rheum officinale</italic> and <italic>Polygonum multiflorum</italic> was also able to block the S-protein binding with ACE-2 receptor in SARS coronavirus [<xref rid="bib102" ref-type="bibr">102</xref>]. Anthraquinone derivatives such as hypericin are effective against various other viruses like herpes simplex virus, vaccinia virus and parainfluenza virus [<xref rid="bib171" ref-type="bibr">171</xref>,<xref rid="bib172" ref-type="bibr">172</xref>].</p><p id="p0165">Various computational tools showed the data of phytoconstituents from different medicinal plants against various therapeutic targets of COVID-19 and thus could be effective against this viral disease. Various types of phytoconstituents investigated through <italic>in silico</italic> docking studies in the SARS-CoV-2 are listed in <xref rid="tbl4" ref-type="table">Table 4</xref>
.<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>List of phytoconstituents screened via <italic>in silico</italic> studies against targets of SARS-CoV-2.</p></caption><alt-text id="alttext0340">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Compound<hr/></th><th>Structure<hr/></th><th>Source<hr/></th><th>Mechanism<hr/></th><th>Refs.<hr/></th></tr><tr><th colspan="5"><bold>Flavonoids</bold></th></tr></thead><tbody><tr><td align="left">Myricitrin</td><td align="left"><inline-graphic xlink:href="fx59_lrg.gif"><alt-text id="alttext0345">Image 59</alt-text></inline-graphic></td><td align="left"><italic>Myrica cerifera</italic></td><td align="left">interacts with 3CLPro</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">3,5,7,3&#x02032;,4&#x02032;,5&#x02032;-hexahydroxy flavanone-3-O-beta-D-gluco-pyranoside</td><td align="left"><inline-graphic xlink:href="fx60_lrg.gif"><alt-text id="alttext0350">Image 60</alt-text></inline-graphic></td><td align="left"><italic>Phaseolus vulgaris</italic></td><td align="left">protease inhibition</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">(2S)-Eriodictyol 7-O-(6&#x02033;-O-galloyl)-beta-D-glucopyranoside</td><td align="left"><inline-graphic xlink:href="fx61_lrg.gif"><alt-text id="alttext0355">Image 61</alt-text></inline-graphic></td><td align="left"><italic>Phyllanthus emblica</italic></td><td align="left">protease inhibition</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Calceolarioside B</td><td align="left"><inline-graphic xlink:href="fx62_lrg.gif"><alt-text id="alttext0360">Image 62</alt-text></inline-graphic></td><td align="left"><italic>Fraxinus sieboldiana</italic></td><td align="left">interact with HIS41<break/>and Cys145</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Kaempferol</td><td align="left"><inline-graphic xlink:href="fx63_lrg.gif"><alt-text id="alttext0365">Image 63</alt-text></inline-graphic></td><td align="left"><italic>Securigera securidaca</italic></td><td align="left">PLpro &#x00026; 3CLpro</td><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Quercetin</td><td align="left"><inline-graphic xlink:href="fx64_lrg.gif"><alt-text id="alttext0370">Image 64</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">PLpro &#x00026; 3CLpro</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Myricetin 3-O-beta-D-glucopyranoside</td><td align="left"><inline-graphic xlink:href="fx65_lrg.gif"><alt-text id="alttext0375">Image 65</alt-text></inline-graphic></td><td align="left"><italic>Camellia sinensis</italic></td><td align="left">3CL Pro inhibition</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Licoleafol</td><td align="left"><inline-graphic xlink:href="fx66_lrg.gif"><alt-text id="alttext0380">Image 66</alt-text></inline-graphic></td><td align="left"><italic>Glycyrrhiza uralensis</italic></td><td align="left">3CL Pro inhibition</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Taiwan-homoflavone A</td><td align="left"><inline-graphic xlink:href="fx67_lrg.gif"><alt-text id="alttext0385">Image 67</alt-text></inline-graphic></td><td align="left"><italic>Cephalotaxus wilsoniana</italic></td><td align="left">Binds with 3CL pro and ACE2</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Afzelin</td><td align="left"><inline-graphic xlink:href="fx68_lrg.gif"><alt-text id="alttext0390">Image 68</alt-text></inline-graphic></td><td/><td align="left">3CL Pro inhibition and ACE2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left">Isoquercitrin</td><td align="left"><inline-graphic xlink:href="fx69_lrg.gif"><alt-text id="alttext0395">Image 69</alt-text></inline-graphic></td><td/><td align="left">3CL Pro inhibition and ACE2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left">Amentoflavone</td><td align="left"><inline-graphic xlink:href="fx70_lrg.gif"><alt-text id="alttext0400">Image 70</alt-text></inline-graphic></td><td/><td align="left">3CL Pro inhibition and ACE-2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left">Nympholide A</td><td align="left"><inline-graphic xlink:href="fx71_lrg.gif"><alt-text id="alttext0405">Image 71</alt-text></inline-graphic></td><td align="left">Aquatic plant</td><td align="left">M<sup>pro</sup>&#x000a0;and RdRp</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Biorobin</td><td align="left"><inline-graphic xlink:href="fx72_lrg.gif"><alt-text id="alttext0410">Image 72</alt-text></inline-graphic></td><td align="left"><italic>Acalypha indica</italic></td><td align="left">RdRp and hACE-2</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Luteolin-7-glucoside</td><td align="left"><inline-graphic xlink:href="fx73_lrg.gif"><alt-text id="alttext0415">Image 73</alt-text></inline-graphic></td><td align="left"><italic>Olea europaea L</italic></td><td align="left">Mpro inhibitor</td><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Naringenin</td><td align="left"><inline-graphic xlink:href="fx74_lrg.gif"><alt-text id="alttext0420">Image 74</alt-text></inline-graphic></td><td align="left"><italic>Citrus sinensis</italic></td><td align="left">Mpro inhibitor</td><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Apigenine-7-glucoside</td><td align="left"><inline-graphic xlink:href="fx75_lrg.gif"><alt-text id="alttext0425">Image 75</alt-text></inline-graphic></td><td align="left"><italic>Averrhoa belimbi</italic></td><td align="left">Mpro inhibitor</td><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Silybin</td><td align="left"><inline-graphic xlink:href="fx76_lrg.gif"><alt-text id="alttext0430">Image 76</alt-text></inline-graphic></td><td align="left"><italic>Silybum marianum</italic></td><td align="left">spike protein inhibition (TMPRSS2)</td><td align="left">[<xref rid="bib175" ref-type="bibr">175</xref>]</td></tr><tr><td align="left">5,7-Dimethoxy flavan-4-O-&#x003b2;-D-glucopyranoside</td><td align="left"><inline-graphic xlink:href="fx77_lrg.gif"><alt-text id="alttext0435">Image 77</alt-text></inline-graphic></td><td/><td align="left">inhibit Mpro</td><td align="left">[<xref rid="bib33" ref-type="bibr">33</xref>]</td></tr><tr><td align="left">Baicalin</td><td align="left"><inline-graphic xlink:href="fx78_lrg.gif"><alt-text id="alttext0440">Image 78</alt-text></inline-graphic></td><td/><td align="left">binds with TMPRSS2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Isoflavonoids</bold></td></tr><tr><td align="left">5,7,3',4'-Tetrahydroxy-2'-(3,3-dimethylallyl) isoflavone</td><td align="left"><inline-graphic xlink:href="fx79_lrg.gif"><alt-text id="alttext0445">Image 79</alt-text></inline-graphic></td><td align="left"><italic>Psorothamnus sp.</italic></td><td align="left">interacts with 3CLPro</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Daidzein</td><td align="left"><inline-graphic xlink:href="fx80_lrg.gif"><alt-text id="alttext0450">Image 80</alt-text></inline-graphic></td><td align="left"><italic>Cicer&#x000a0;arietinum</italic></td><td align="left">Blocks HSPA5</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">Genistein</td><td align="left"><inline-graphic xlink:href="fx81_lrg.gif"><alt-text id="alttext0455">Image 81</alt-text></inline-graphic></td><td align="left"><italic>Cicer&#x000a0;arietinum</italic></td><td align="left">Blocks HSPA5</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">Formononetin</td><td align="left"><inline-graphic xlink:href="fx82_lrg.gif"><alt-text id="alttext0460">Image 82</alt-text></inline-graphic></td><td align="left"><italic>Cicer&#x000a0;arietinum</italic></td><td align="left">Blocks HSPA5</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">Biochanin A</td><td align="left"><inline-graphic xlink:href="fx83_lrg.gif"><alt-text id="alttext0465">Image 83</alt-text></inline-graphic></td><td align="left"><italic>Cicer&#x000a0;arietinum</italic></td><td align="left">Blocks HSPA5</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">Nictoflorin</td><td align="left"><inline-graphic xlink:href="fx84_lrg.gif"><alt-text id="alttext0470">Image 84</alt-text></inline-graphic></td><td align="left"><italic>Nyctanthes arbortristis</italic></td><td align="left">interact with protease</td><td align="left">[<xref rid="bib125" ref-type="bibr">125</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Terpenoids</bold></td></tr><tr><td align="left">Betulinic acid</td><td align="left"><inline-graphic xlink:href="fx85_lrg.gif"><alt-text id="alttext0475">Image 85</alt-text></inline-graphic></td><td align="left">Chinese medicinal plant</td><td align="left">replication &#x00026;3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Crypto-tanshinone</td><td align="left"><inline-graphic xlink:href="fx86_lrg.gif"><alt-text id="alttext0480">Image 86</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">PLpro &#x00026; 3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Dihydro-tanshinone</td><td align="left"><inline-graphic xlink:href="fx87_lrg.gif"><alt-text id="alttext0485">Image 87</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">entry &#x00026; spike protein</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Sugiol</td><td align="left"><inline-graphic xlink:href="fx88_lrg.gif"><alt-text id="alttext0490">Image 88</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">Replication<break/>&#x00026; 3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Tanshinone IIA</td><td align="left"><inline-graphic xlink:href="fx89_lrg.gif"><alt-text id="alttext0495">Image 89</alt-text></inline-graphic></td><td align="left">Chinese medicinal plant</td><td align="left">PLpro &#x00026; 3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Nimolicinol</td><td align="left"><inline-graphic xlink:href="fx90_lrg.gif"><alt-text id="alttext0500">Image 90</alt-text></inline-graphic></td><td align="left"><italic>Azadirachta indica</italic></td><td align="left">protease inhibition</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Lactucopicrin</td><td align="left"><inline-graphic xlink:href="fx91_lrg.gif"><alt-text id="alttext0505">Image 91</alt-text></inline-graphic></td><td align="left"><italic>Lactuca virosa</italic></td><td align="left">3CL Pro inhibition and ACE2</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Cordioside</td><td align="left"><inline-graphic xlink:href="fx92_lrg.gif"><alt-text id="alttext0510">Image 92</alt-text></inline-graphic></td><td align="left"><italic>Tinospora cordifolia</italic></td><td align="left"><italic>binds with main protease</italic></td><td align="left">[<xref rid="bib175" ref-type="bibr">175</xref>]</td></tr><tr><td align="left">Vindolinine</td><td align="left"><inline-graphic xlink:href="fx93_lrg.gif"><alt-text id="alttext0515">Image 93</alt-text></inline-graphic></td><td align="left"><italic>Catharanthus roseus</italic></td><td align="left">binds with NSP15</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Camphorating D</td><td align="left"><inline-graphic xlink:href="fx94_lrg.gif"><alt-text id="alttext0520">Image 94</alt-text></inline-graphic></td><td align="left"><italic>Cinnamomum verum</italic></td><td align="left">blocking signalling pathway</td><td align="left">[<xref rid="bib169" ref-type="bibr">169</xref>]</td></tr><tr><td align="left">Bonducellpin D</td><td align="left"><inline-graphic xlink:href="fx95_lrg.gif"><alt-text id="alttext0525">Image 95</alt-text></inline-graphic></td><td/><td align="left">inhibit Mpro</td><td align="left">Gurung et al., 2020</td></tr><tr><td align="left">Nimbin</td><td align="left"><inline-graphic xlink:href="fx96_lrg.gif"><alt-text id="alttext0530">Image 96</alt-text></inline-graphic></td><td align="left"><italic>Azadirachta indica</italic></td><td align="left">Interact with protease</td><td align="left">[<xref rid="bib33" ref-type="bibr">33</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Alkaloids</bold></td></tr><tr><td align="left">Desmethoxy-reserpine</td><td align="left"><inline-graphic xlink:href="fx97_lrg.gif"><alt-text id="alttext0535">Image 97</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">Replication, 3CLpro &#x00026; entry</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Moupinamide</td><td align="left"><inline-graphic xlink:href="fx98_lrg.gif"><alt-text id="alttext0540">Image 98</alt-text></inline-graphic></td><td align="left"><italic>Piper nigru</italic></td><td align="left">PLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Amaranthin</td><td align="left"><inline-graphic xlink:href="fx99_lrg.gif"><alt-text id="alttext0545">Image 99</alt-text></inline-graphic></td><td align="left"><italic>Amaranthus tricolor</italic></td><td align="left">3CL Pro inhibition</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Oriciacridone F</td><td align="left"><inline-graphic xlink:href="fx100_lrg.gif"><alt-text id="alttext0550">Image 100</alt-text></inline-graphic></td><td/><td align="left">binds with 3CL and ACE2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left">Somniferine</td><td align="left"><inline-graphic xlink:href="fx101_lrg.gif"><alt-text id="alttext0555">Image 101</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP15</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">2,3-Dehydro-somnifericin</td><td align="left"><inline-graphic xlink:href="fx102_lrg.gif"><alt-text id="alttext0560">Image 102</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP3</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Anaferine</td><td align="left"><inline-graphic xlink:href="fx103_lrg.gif"><alt-text id="alttext0565">Image 103</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP10, NSP16</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Berberine</td><td align="left"><inline-graphic xlink:href="fx104_lrg.gif"><alt-text id="alttext0570">Image 104</alt-text></inline-graphic></td><td align="left"><italic>Tinospora cordifolia</italic></td><td align="left">interact with protease</td><td align="left">[<xref rid="bib125" ref-type="bibr">125</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Phenolic compounds</bold></td></tr><tr><td align="left">Theaflavin</td><td align="left"><inline-graphic xlink:href="fx105_lrg.gif"><alt-text id="alttext0575">Image 105</alt-text></inline-graphic></td><td align="left"><italic>Camellia sinensis</italic></td><td align="left">binds with RdRp</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Methyl rosmarinate</td><td align="left"><inline-graphic xlink:href="fx106_lrg.gif"><alt-text id="alttext0580">Image 106</alt-text></inline-graphic></td><td align="left"><italic>Hyptis atrorubens</italic></td><td align="left">interacts with 3CLPro</td><td align="left">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left">Coumaroyl-tyramine</td><td align="left"><inline-graphic xlink:href="fx107_lrg.gif"><alt-text id="alttext0585">Image 107</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">PLpro &#x00026; 3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Lignan</td><td align="left"><inline-graphic xlink:href="fx108_lrg.gif"><alt-text id="alttext0590">Image 108</alt-text></inline-graphic></td><td align="left">Chinese medicinal Plant</td><td align="left">replication &#x00026; 3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left">Demethoxy-curcumin</td><td align="left"><inline-graphic xlink:href="fx109_lrg.gif"><alt-text id="alttext0595">Image 109</alt-text></inline-graphic></td><td align="left"><italic>Curcuma longa</italic></td><td align="left">Mpro inhibitor</td><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left">Aloenin</td><td align="left"><inline-graphic xlink:href="fx110_lrg.gif"><alt-text id="alttext0600">Image 110</alt-text></inline-graphic></td><td align="left"><italic>Aloe Vera</italic></td><td align="left">interact with protease</td><td align="left">[<xref rid="bib125" ref-type="bibr">125</xref>]</td></tr><tr><td align="left">Gingerol</td><td align="left"><inline-graphic xlink:href="fx111_lrg.gif"><alt-text id="alttext0605">Image 111</alt-text></inline-graphic></td><td align="left"><italic>Zingiber officinale</italic></td><td align="left">Interact with protease</td><td align="left">[<xref rid="bib125" ref-type="bibr">125</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Steroidal compounds</bold></td></tr><tr><td align="left">27-Deoxy-14- hydroxy withaferin A</td><td align="left"><inline-graphic xlink:href="fx112_lrg.gif"><alt-text id="alttext0610">Image 112</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">protease inhibition</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">27-Hydroxy withanone</td><td align="left"><inline-graphic xlink:href="fx113_lrg.gif"><alt-text id="alttext0615">Image 113</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">interferes with Spike protein</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">12-Deoxy witha-stramonolide</td><td align="left"><inline-graphic xlink:href="fx114_lrg.gif"><alt-text id="alttext0620">Image 114</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">interferes with Spike protein and binds with NSP9</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">27-Deoxy withaferin A</td><td align="left"><inline-graphic xlink:href="fx115_lrg.gif"><alt-text id="alttext0625">Image 115</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">interferes with Spike protein</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">2,3-Dihydro withaferin A</td><td align="left"><inline-graphic xlink:href="fx116_lrg.gif"><alt-text id="alttext0630">Image 116</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">interfers with Spike</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">27-Hydroxy withanolide B</td><td align="left"><inline-graphic xlink:href="fx117_lrg.gif"><alt-text id="alttext0635">Image 117</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP10</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Witha-stramonolide</td><td align="left"><inline-graphic xlink:href="fx118_lrg.gif"><alt-text id="alttext0640">Image 118</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP12 D2</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Withanolide B</td><td align="left"><inline-graphic xlink:href="fx119_lrg.gif"><alt-text id="alttext0645">Image 119</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP12 D2 and binds with NSP3</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Withanolide R</td><td align="left"><inline-graphic xlink:href="fx120_lrg.gif"><alt-text id="alttext0650">Image 120</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP12 D2</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Withaferin A</td><td align="left"><inline-graphic xlink:href="fx121_lrg.gif"><alt-text id="alttext0655">Image 121</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP12 D2</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">27-Hydroxy withanolide B</td><td align="left"><inline-graphic xlink:href="fx122_lrg.gif"><alt-text id="alttext0660">Image 122</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP9</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Aza-diradionolide</td><td align="left"><inline-graphic xlink:href="fx123_lrg.gif"><alt-text id="alttext0665">Image 123</alt-text></inline-graphic></td><td align="left"><italic>Azadirachta indica</italic></td><td align="left">binds with NSP9</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">27-Deoxy-14-hydroxyl withaferin A</td><td align="left"><inline-graphic xlink:href="fx124_lrg.gif"><alt-text id="alttext0670">Image 124</alt-text></inline-graphic></td><td align="left"><italic>Withania somnifera</italic></td><td align="left">binds with NSP3</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Anthraquinones</bold></td></tr><tr><td align="left">Microcarpin</td><td align="left"><inline-graphic xlink:href="fx125_lrg.gif"><alt-text id="alttext0675">Image 125</alt-text></inline-graphic></td><td/><td align="left">binds with TMPRSS2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Anthocyanins</bold></td></tr><tr><td align="left">Chry-santhemin</td><td align="left"><inline-graphic xlink:href="fx126_lrg.gif"><alt-text id="alttext0680">Image 126</alt-text></inline-graphic></td><td align="left">Black grapes</td><td align="left">RdRp and hACE-2</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Stilbenes</bold></td></tr><tr><td align="left">&#x003b4;-Viniferin</td><td align="left"><inline-graphic xlink:href="fx127_lrg.gif"><alt-text id="alttext0685">Image 127</alt-text></inline-graphic></td><td align="left">Grapevine leaves</td><td align="left">M<sup>Pro</sup>, RdRp and hACE-2</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Iso-gemichalcone</td><td align="left"><inline-graphic xlink:href="fx128_lrg.gif"><alt-text id="alttext0690">Image 128</alt-text></inline-graphic></td><td/><td align="left">binds with TMPRSS2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Lactones</bold></td></tr><tr><td align="left">Limonin</td><td align="left"><inline-graphic xlink:href="fx129_lrg.gif"><alt-text id="alttext0695">Image 129</alt-text></inline-graphic></td><td align="left"><italic>Nigella sativa</italic></td><td align="left">binds with NSP16</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Durumolide K</td><td align="left"><inline-graphic xlink:href="fx130_lrg.gif"><alt-text id="alttext0700">Image 130</alt-text></inline-graphic></td><td/><td align="left">binds with TMPRSS2</td><td align="left">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Fatty acids</bold></td></tr><tr><td align="left">Dihomo-gamma-linolenic acid</td><td align="left"><inline-graphic xlink:href="fx131_lrg.gif"><alt-text id="alttext0705">Image 131</alt-text></inline-graphic></td><td align="left">Chinese medicinal plant</td><td align="left">3CLpro</td><td align="left">[<xref rid="bib11" ref-type="bibr">11</xref>]</td></tr><tr><td colspan="5" align="left"><bold>Phthalates</bold></td></tr><tr><td align="left">Solvanol</td><td align="left"><inline-graphic xlink:href="fx132_lrg.gif"><alt-text id="alttext0710">Image 132</alt-text></inline-graphic></td><td align="left"><italic>Solanum nigrum</italic></td><td align="left">binds with NSP16</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec3"><label>3</label><title>Conclusions</title><p id="p0170">In current adverse conditions of COVID-19 across the world, it is the urgent need of time to develop drugs or therapeutic options at the earliest. Developing new drugs and identifying novel drug targets are indeed time consuming and validation of such novel drugs/targets in clinical trials are mandatory to check their efficacy and effectiveness. Unavailability of the drugs and specific treatments for COVID-19 till date motivate the researchers to look for alternatives for successfully combating the current disease scenario. In this regard, medicinal plants containing specific phytomoieties could provide a wide scope as therapeutic drugs against COVID-19. Furthermore, the low toxicity of herbal medicines and an easy development process provide additional advantages in their fast and wide usage. This study has compiled a data of different types of phytoconstituents possessing antiviral activity against Coronaviruses as well as phytoconstituents showing affinities against therapeutic targets of SARS-CoV-2 like RdRP, 3CLpro, PLpro and the host cell targets like ACE-2 based on the computational screening methods. However, further <italic>in vivo</italic> and in vitro studies need to be done to confirm the bioactivity of these compounds against COVID-19. Overall, the development of phytopharmaceuticals as an alternative approach could be seen as a viable treatment option against SARS-CoV-2 in current COVID-19 pandemic.</p></sec><sec id="sec4"><title>Funding information</title><p id="p0175">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0180">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><chapter-title>WHO coronavirus disease (COVID-19) dashboard</chapter-title><year>2020</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/" id="intref0015">https://covid19.who.int/</ext-link></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Ratten</surname><given-names>V.</given-names></name></person-group><article-title>Coronavirus (covid-19) and entrepreneurship: changing life and work landscape</article-title><source>J. Small Bus. Enterpren.</source><volume>32</volume><year>2020</year><fpage>503</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1080/08276331.2020.1790167</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="book" id="sref3"><person-group person-group-type="author"><name><surname>Barua</surname><given-names>S.</given-names></name></person-group><chapter-title>Understanding Coronanomics: the economic implications of the coronavirus (COVID-19) pandemic</chapter-title><year>2020</year><publisher-name>SSRN</publisher-name><pub-id pub-id-type="doi">10.2139/ssrn.3566477</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title><source>Acta Pharm. Sin. B</source><volume>10</volume><year>2020</year><fpage>766</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.008</pub-id><pub-id pub-id-type="pmid">32292689</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>Q.</given-names></name></person-group><article-title>Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID&#x02010;19) implicate special control measures</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1002/jmv.25748</pub-id><pub-id pub-id-type="pmid">32134116</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Ogen</surname><given-names>Y.</given-names></name></person-group><article-title>Assessing nitrogen dioxide (NO<sub>2</sub>) levels as a contributing factor to the coronavirus (COVID-19) fatality rate</article-title><source>Sci. Total Environ.</source><volume>726</volume><year>2020</year><fpage>138605</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138605</pub-id><pub-id pub-id-type="pmid">32302812</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Onder</surname><given-names>G.</given-names></name><name><surname>Rezza</surname><given-names>G.</given-names></name><name><surname>Brusaferro</surname><given-names>S.</given-names></name></person-group><article-title>Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy</article-title><source>J. Am. Med. Assoc.</source><volume>323</volume><issue>18</issue><year>2020</year><fpage>1775</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4683</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Decaro</surname><given-names>N.</given-names></name><name><surname>Lorusso</surname><given-names>A.</given-names></name></person-group><article-title>Novel human coronavirus (SARS-CoV-2): a lesson from animal coronaviruses</article-title><source>Vet. Microbiol.</source><volume>244</volume><year>2020</year><fpage>108693</fpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2020.108693</pub-id><pub-id pub-id-type="pmid">32402329</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Helmy</surname><given-names>Y.A.</given-names></name><name><surname>Fawzy</surname><given-names>M.</given-names></name><name><surname>Elaswad</surname><given-names>A.</given-names></name><name><surname>Sobieh</surname><given-names>A.</given-names></name><name><surname>Kenney</surname><given-names>S.P.</given-names></name><name><surname>Shehata</surname><given-names>A.A.</given-names></name></person-group><article-title>The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control</article-title><source>J. Clin. Med.</source><volume>9</volume><issue>4</issue><year>2020</year><fpage>1225</fpage><pub-id pub-id-type="doi">10.3390/jcm9041225</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Donaldson</surname><given-names>E.F.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>11</volume><issue>12</issue><year>2013</year><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3143</pub-id><pub-id pub-id-type="pmid">24217413</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>J.S.</given-names></name><name><surname>Johnson</surname><given-names>J.B.</given-names></name><name><surname>Steel</surname><given-names>J.C.</given-names></name><name><surname>Broszczak</surname><given-names>D.A.</given-names></name><name><surname>Neilsen</surname><given-names>P.M.</given-names></name><name><surname>Walsh</surname><given-names>K.B.</given-names></name><name><surname>Naiker</surname><given-names>M.</given-names></name></person-group><article-title>Natural product-derived phytochemicals as potential agents against coronaviruses: a review</article-title><source>Virus Res.</source><volume>284</volume><year>2020</year><fpage>197989</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2020.197989</pub-id><pub-id pub-id-type="pmid">32360300</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Abd El-Aziz</surname><given-names>T.M.</given-names></name><name><surname>Stockand</surname><given-names>J.D.</given-names></name></person-group><article-title>Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status</article-title><source>Infect. Genet. Evol.</source><volume>83</volume><year>2020</year><fpage>104327</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104327</pub-id><pub-id pub-id-type="pmid">32320825</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>A.</given-names></name><name><surname>Nikam</surname><given-names>A.N.</given-names></name><name><surname>Shreya</surname><given-names>A.B.</given-names></name><name><surname>Mutalik</surname><given-names>S.P.</given-names></name><name><surname>Gopalan</surname><given-names>D.</given-names></name><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Padya</surname><given-names>B.S.</given-names></name><name><surname>Fernandes</surname><given-names>G.</given-names></name><name><surname>Mutalik</surname><given-names>S.</given-names></name><name><surname>Prassl</surname><given-names>R.</given-names></name></person-group><article-title>Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements</article-title><source>Life Sci.</source><volume>256</volume><year>2020</year><fpage>117883</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117883</pub-id><pub-id pub-id-type="pmid">32497632</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>N.</given-names></name><name><surname>Viceconte</surname><given-names>G.</given-names></name><name><surname>Ergonul</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Petersen</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19, SARS and MERS: are they closely related?</article-title><source>Clin. Microbiol. Infect.</source><volume>26</volume><issue>6</issue><year>2020</year><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.026</pub-id><pub-id pub-id-type="pmid">32234451</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.Z.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.035</pub-id><pub-id pub-id-type="pmid">32220310</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><comment>10223</comment><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Vellingiri</surname><given-names>B.</given-names></name><name><surname>Jayaramayya</surname><given-names>K.</given-names></name><name><surname>Iyer</surname><given-names>M.</given-names></name><name><surname>Narayanasamy</surname><given-names>A.</given-names></name><name><surname>Govindasamy</surname><given-names>V.</given-names></name><name><surname>Giridharan</surname><given-names>B.</given-names></name><name><surname>Ganesan</surname><given-names>S.</given-names></name><name><surname>Venugopal</surname><given-names>A.</given-names></name><name><surname>Venkatesan</surname><given-names>D.</given-names></name><name><surname>Ganesan</surname><given-names>H.</given-names></name><name><surname>Rajagopalan</surname><given-names>K.</given-names></name><name><surname>Rahman</surname><given-names>P.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name></person-group><article-title>COVID-19: a promising cure for the global panic</article-title><source>Sci. Total Environ.</source><volume>725</volume><year>2020</year><fpage>138277</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138277</pub-id><pub-id pub-id-type="pmid">32278175</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>H.M.</given-names></name><name><surname>Elkhatib</surname><given-names>W.F.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Elshabrawy</surname><given-names>H.A.</given-names></name></person-group><article-title>Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks</article-title><source>Pathogens</source><volume>9</volume><issue>3</issue><year>2020</year><fpage>186</fpage><pub-id pub-id-type="doi">10.3390/pathogens9030186</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Carstens</surname><given-names>E.B.</given-names></name></person-group><article-title>Ratification vote on taxonomic proposals to the international committee on taxonomy of viruses (2009)</article-title><source>Arch. Virol.</source><volume>155</volume><issue>1</issue><year>2010</year><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1007/s00705-009-0547-x</pub-id><pub-id pub-id-type="pmid">19960211</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><issue>3</issue><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Coronavirus diversity, phylogeny and interspecies jumping</article-title><source>Exp. Biol. Med.</source><volume>234</volume><issue>10</issue><year>2009</year><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.3181/0903-MR-94</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zu</surname><given-names>R.</given-names></name><name><surname>Huo</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cardona</surname><given-names>C.J.</given-names></name><name><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Antigenic and genetic characterization of a European avian-like H1N1 swine influenza virus from a boy in China in 2011</article-title><source>Arch. Virol.</source><volume>158</volume><issue>1</issue><year>2013</year><fpage>39</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s00705-012-1423-7</pub-id><pub-id pub-id-type="pmid">22935945</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name></person-group><article-title>Hosts and sources of endemic human coronaviruses</article-title><source>Adv. Virus Res.</source><volume>100</volume><year>2018</year><fpage>163</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2018.01.001</pub-id><pub-id pub-id-type="pmid">29551135</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>From SARS coronavirus to novel animal and human coronaviruses</article-title><source>J. Thorac. Dis.</source><volume>5</volume><issue>Suppl2</issue><year>2013</year><fpage>S103</fpage><lpage>S108</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2072-1439.2013.06.02</pub-id><pub-id pub-id-type="pmid">23977429</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z.W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.S.</given-names></name><name><surname>Fung</surname><given-names>S.Y.</given-names></name><name><surname>Chan</surname><given-names>C.P.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Zoonotic origins of human coronaviruses</article-title><source>Int. J. Biol. Sci.</source><volume>16</volume><issue>10</issue><year>2020</year><fpage>1686</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.7150/ijbs.45472</pub-id><pub-id pub-id-type="pmid">32226286</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>R.H.</given-names></name><name><surname>Kuhn</surname><given-names>R.J.</given-names></name><name><surname>Olson</surname><given-names>N.H.</given-names></name><name><surname>Rossmann</surname><given-names>M.G.</given-names></name><name><surname>Choi</surname><given-names>H.K.</given-names></name><name><surname>Smith</surname><given-names>T.J.</given-names></name><name><surname>Baker</surname><given-names>T.S.</given-names></name></person-group><article-title>Nucleocapsid and glycoprotein organization in an enveloped virus</article-title><source>Cell</source><volume>80</volume><issue>4</issue><year>1995</year><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90516-2</pub-id><pub-id pub-id-type="pmid">7867069</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Naqvi</surname><given-names>A.A.T.</given-names></name><name><surname>Fatima</surname><given-names>K.</given-names></name><name><surname>Mohammad</surname><given-names>T.</given-names></name><name><surname>Fatima</surname><given-names>U.</given-names></name><name><surname>Singh</surname><given-names>I.K.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Atif</surname><given-names>S.M.</given-names></name><name><surname>Hariprasad</surname><given-names>G.</given-names></name><name><surname>Hasan</surname><given-names>G.M.</given-names></name><name><surname>Hassan</surname><given-names>M.I.</given-names></name></person-group><article-title>Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach</article-title><source>Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.</source><volume>1866</volume><issue>10</issue><year>2020</year><fpage>165878</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165878</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annual Review of Virology</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Abduljalil</surname><given-names>J.M.</given-names></name><name><surname>Abduljalil</surname><given-names>B.M.</given-names></name></person-group><article-title>Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view</article-title><source>New Microbes and New Infections</source><volume>35</volume><year>2020</year><fpage>100672</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2020.100672</pub-id><pub-id pub-id-type="pmid">32322400</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="book" id="sref30"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Duan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>Z.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name></person-group><chapter-title>On the origin and continuing evolution of SARS-CoV-2</chapter-title><year>2020</year><publisher-name>National Science Review</publisher-name><pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id><comment>2020, nwaa036</comment></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Chhikara</surname><given-names>B.S.</given-names></name><name><surname>Rathi</surname><given-names>B.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Poonam</surname></name></person-group><article-title>Corona virus SARS-CoV-2 disease COVID-19: infection, prevention and clinical advances of the prospective chemical drug therapeutics</article-title><source>Chemical Biology Letters</source><volume>7</volume><issue>1</issue><year>2020</year><fpage>63</fpage><lpage>72</lpage></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Gyawali</surname><given-names>R.</given-names></name><name><surname>Paudel</surname><given-names>P.N.</given-names></name><name><surname>Basyal</surname><given-names>D.</given-names></name><name><surname>Setzer</surname><given-names>W.N.</given-names></name><name><surname>Lamichhane</surname><given-names>S.</given-names></name><name><surname>Paudel</surname><given-names>M.N.</given-names></name><name><surname>Gyawali</surname><given-names>S.</given-names></name><name><surname>Khanal</surname><given-names>P.</given-names></name></person-group><article-title>A review on ayurvedic medicinal herbs as remedial perspective for COVID-19</article-title><source>JKAHS</source><volume>3</volume><year>2020</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.3126/jkahs.v3i0.29116</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Gurung</surname><given-names>A.B.</given-names></name><name><surname>Ali</surname><given-names>M.A.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Farah</surname><given-names>M.A.</given-names></name><name><surname>MashayAl-Anazi</surname><given-names>K.</given-names></name></person-group><article-title>Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach</article-title><source>Life Sci.</source><volume>255</volume><year>2020</year><fpage>117831</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117831</pub-id><pub-id pub-id-type="pmid">32450166</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Kabera</surname><given-names>J.N.</given-names></name><name><surname>Semana</surname><given-names>E.</given-names></name><name><surname>Mussa</surname><given-names>A.R.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name></person-group><article-title>Plant secondary metabolites: biosynthesis, classification, function and pharmacological properties</article-title><source>J. Pharm. Pharmacol.</source><volume>2</volume><year>2014</year><fpage>377</fpage><lpage>392</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="book" id="sref35"><person-group person-group-type="author"><name><surname>Parida</surname><given-names>P.K.</given-names></name><name><surname>Paul</surname><given-names>D.</given-names></name><name><surname>Chakravorty</surname><given-names>D.</given-names></name></person-group><chapter-title>Nature to nurture-identifying phytochemicals from Indian medicinal plants as prophylactic medicine by rational screening to be potent against multiple drug targets of SARS-CoV-2</chapter-title><year>2020</year><publisher-name>ChemRxiv</publisher-name><pub-id pub-id-type="doi">10.26434/chemrxiv.12355937.v1</pub-id><comment>2020, (Pre-print)</comment></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Millet</surname><given-names>J.K.</given-names></name><name><surname>Licitra</surname><given-names>B.N.</given-names></name><name><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title><source>Viruses</source><volume>4</volume><issue>6</issue><year>2012</year><fpage>1011</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3390/v4061011</pub-id><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>van der Zee</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>C.</given-names></name><name><surname>Rottier</surname><given-names>P.</given-names></name></person-group><article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title><source>J. Virol.</source><volume>77</volume><issue>16</issue><year>2013</year><fpage>8801</fpage><lpage>8811</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.16.8801-8811.2003</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J. Pathol.</source><volume>203</volume><issue>2</issue><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/path.1570</pub-id><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Heald-Sargent</surname><given-names>T.</given-names></name><name><surname>Gallagher</surname><given-names>T.</given-names></name></person-group><article-title>Ready, set, fuse! the coronavirus spike protein and acquisition of fusion competence</article-title><source>Viruses</source><volume>4</volume><year>2012</year><fpage>557</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.3390/v4040557</pub-id><pub-id pub-id-type="pmid">22590686</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>White</surname><given-names>J.M.</given-names></name><name><surname>Delos</surname><given-names>S.E.</given-names></name><name><surname>Brecher</surname><given-names>M.</given-names></name><name><surname>Schornberg</surname><given-names>K.</given-names></name></person-group><article-title>Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme</article-title><source>Crit. Rev. Biochem. Mol. Biol.</source><volume>43</volume><issue>3</issue><year>2008</year><fpage>189</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1080/10409230802058320</pub-id><pub-id pub-id-type="pmid">18568847</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>S.</given-names></name><name><surname>Glowacka</surname><given-names>I.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Lavender</surname><given-names>H.</given-names></name><name><surname>Gnirss</surname><given-names>K.</given-names></name><name><surname>Nehlmeier</surname><given-names>I.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Soilleux</surname><given-names>E.J.</given-names></name><name><surname>Jahn</surname><given-names>O.</given-names></name><name><surname>Steffen</surname><given-names>I.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease</article-title><source>J. Virol.</source><volume>85</volume><issue>24</issue><year>2011</year><fpage>13363</fpage><lpage>13372</lpage><pub-id pub-id-type="doi">10.1128/JVI.05300-11</pub-id><pub-id pub-id-type="pmid">21994442</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Shulla</surname><given-names>A.</given-names></name><name><surname>Heald-Sargent</surname><given-names>T.</given-names></name><name><surname>Subramanya</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Gallagher</surname><given-names>T.</given-names></name></person-group><article-title>A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry</article-title><source>J. Virol.</source><volume>85</volume><issue>2</issue><year>2011</year><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1128/JVI.02062-10</pub-id><pub-id pub-id-type="pmid">21068237</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat. Rev. Drug Discov.</source><volume>19</volume><issue>3</issue><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>Y.L.</given-names></name><name><surname>Teoh</surname><given-names>K.T.</given-names></name><name><surname>Lo</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>C.M.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><name><surname>Tsao</surname><given-names>S.W.</given-names></name><name><surname>Nicholls</surname><given-names>J.M.</given-names></name><name><surname>Altmeyer</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Bruzzone</surname><given-names>R.</given-names></name><name><surname>Nal</surname><given-names>B.</given-names></name></person-group><article-title>The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles</article-title><source>J. Virol.</source><volume>82</volume><issue>22</issue><year>2008</year><fpage>11318</fpage><lpage>11330</lpage><pub-id pub-id-type="doi">10.1128/JVI.01052-08</pub-id><pub-id pub-id-type="pmid">18753196</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name><name><surname>Verdi&#x000e1;-B&#x000e1;guena</surname><given-names>C.</given-names></name><name><surname>Jimenez-Guarde&#x000f1;o</surname><given-names>J.M.</given-names></name><name><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name><surname>Casta&#x000f1;o-Rodriguez</surname><given-names>C.</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name><surname>Torres</surname><given-names>J.</given-names></name><name><surname>Aguilella</surname><given-names>V.M.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome</article-title><source>Virology</source><volume>485</volume><year>2015</year><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.08.010</pub-id><pub-id pub-id-type="pmid">26331680</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Lukassen</surname><given-names>S.</given-names></name><name><surname>Chua</surname><given-names>R.L.</given-names></name><name><surname>Trefzer</surname><given-names>T.</given-names></name><name><surname>Kahn</surname><given-names>N.C.</given-names></name><name><surname>Schneider</surname><given-names>M.A.</given-names></name><name><surname>Muley</surname><given-names>T.</given-names></name><name><surname>Winter</surname><given-names>H.</given-names></name><name><surname>Meister</surname><given-names>M.</given-names></name><name><surname>Veith</surname><given-names>C.</given-names></name><name><surname>Boots</surname><given-names>A.W.</given-names></name><name><surname>Hennig</surname><given-names>B.P.</given-names></name><name><surname>Kreuter</surname><given-names>M.</given-names></name><name><surname>Conrad</surname><given-names>C.</given-names></name><name><surname>Eils</surname><given-names>R.</given-names></name></person-group><article-title>SARS&#x02010;CoV&#x02010;2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells</article-title><source>EMBO J.</source><volume>39</volume><issue>10</issue><year>2020</year><object-id pub-id-type="publisher-id">e105114</object-id><pub-id pub-id-type="doi">10.15252/embj.20105114</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Bourgonje</surname><given-names>A.R.</given-names></name><name><surname>Abdulle</surname><given-names>A.E.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Hillebrands</surname><given-names>J.L.</given-names></name><name><surname>Navis</surname><given-names>G.J.</given-names></name><name><surname>Gordijn</surname><given-names>S.J.</given-names></name><name><surname>Bolling</surname><given-names>M.C.</given-names></name><name><surname>Dijkstra</surname><given-names>G.</given-names></name><name><surname>Voors</surname><given-names>A.A.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>van der Voort</surname><given-names>P.H.</given-names></name><name><surname>Mulder</surname><given-names>D.J.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Angiotensin&#x02010;converting enzyme&#x02010;2 (ACE2), SARS&#x02010;CoV&#x02010;2 and pathophysiology of coronavirus disease 2019 (COVID&#x02010;19)</article-title><source>J. Pathol.</source><volume>251</volume><issue>3</issue><year>2020</year><fpage>228</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/path.5471</pub-id><pub-id pub-id-type="pmid">32418199</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="other" id="sref48"><person-group person-group-type="author"><name><surname>Karthik</surname><given-names>A.R.A.</given-names></name><name><surname>Muthusamy</surname><given-names>V.S.</given-names></name><name><surname>Ramanathan</surname><given-names>M.</given-names></name></person-group><article-title>Phytomolecules having flavone and napthofuran nucleus exhibited better binding G-score against protease and SPIKE protein of novel corona virus COVID-19. Research Square</article-title><comment>2020, (Pre-print)</comment><pub-id pub-id-type="doi">10.21203/rs.3.rs-27206/v1</pub-id><year>2020</year></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>I.</given-names></name><name><surname>Maity</surname><given-names>P.</given-names></name></person-group><article-title>COVID-19 outbreak: migration, effects on society, global environment and prevention</article-title><source>Sci. Total Environ.</source><volume>728</volume><year>2020</year><fpage>138882</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138882</pub-id><pub-id pub-id-type="pmid">32335410</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>M.X.</given-names></name><name><surname>Ang</surname><given-names>I.Y.H.</given-names></name><name><surname>Tan</surname><given-names>S.H.X.</given-names></name><name><surname>Lewis</surname><given-names>R.F.</given-names></name><name><surname>Chen</surname><given-names>J.I.</given-names></name><name><surname>Gutierrez</surname><given-names>R.A.</given-names></name><name><surname>Gwee</surname><given-names>S.X.W.</given-names></name><name><surname>Chua</surname><given-names>P.E.Y.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Ng</surname><given-names>X.Y.</given-names></name><name><surname>Yap</surname><given-names>R.K.</given-names></name><name><surname>Tan</surname><given-names>H.Y.</given-names></name><name><surname>Teo</surname><given-names>Y.Y.</given-names></name><name><surname>Tan</surname><given-names>C.C.</given-names></name><name><surname>Cook</surname><given-names>A.R.</given-names></name><name><surname>Yap</surname><given-names>J.C.</given-names></name><name><surname>Hsu</surname><given-names>L.Y.</given-names></name></person-group><article-title>Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review</article-title><source>J. Clin. Med.</source><volume>9</volume><issue>3</issue><year>2020</year><fpage>623</fpage><pub-id pub-id-type="doi">10.3390/jcm9030623</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Gheblawi</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Viveiros</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>Q.</given-names></name><name><surname>Zhong</surname><given-names>J.C.</given-names></name><name><surname>Turner</surname><given-names>A.J.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name><name><surname>Grant</surname><given-names>M.B.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2</article-title><source>Circ. Res.</source><volume>126</volume><issue>10</issue><year>2020</year><fpage>1456</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317015</pub-id><pub-id pub-id-type="pmid">32264791</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Martin</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title><source>Cell Discovery</source><volume>6</volume><year>2020</year><fpage>14</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med.</source><volume>46</volume><issue>4</issue><year>2020</year><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Poduri</surname><given-names>R.</given-names></name><name><surname>Joshi</surname><given-names>G.</given-names></name><name><surname>Jagadeesh</surname><given-names>G.</given-names></name></person-group><article-title>Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19</article-title><source>Cell. Signal.</source><volume>74</volume><year>2020</year><fpage>109721</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109721</pub-id><pub-id pub-id-type="pmid">32711111</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>R.S.</given-names></name><name><surname>Jagdale</surname><given-names>S.S.</given-names></name><name><surname>Bansode</surname><given-names>S.B.</given-names></name><name><surname>Shankar</surname><given-names>S.S.</given-names></name><name><surname>Tellis</surname><given-names>M.B.</given-names></name><name><surname>Pandya</surname><given-names>V.K.</given-names></name><name><surname>Chugh</surname><given-names>A.</given-names></name><name><surname>Giri</surname><given-names>A.P.</given-names></name><name><surname>Kulkarni</surname><given-names>M.J.</given-names></name></person-group><article-title>Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1760137</pub-id><comment>2020</comment></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Abena</surname><given-names>P.M.</given-names></name><name><surname>Decloedt</surname><given-names>E.H.</given-names></name><name><surname>Bottieau</surname><given-names>E.</given-names></name><name><surname>Suleman</surname><given-names>F.</given-names></name><name><surname>Adejumo</surname><given-names>P.</given-names></name><name><surname>Sam-Agudu</surname><given-names>N.A.</given-names></name><name><surname>Muyembe TamFum</surname><given-names>J.J.</given-names></name><name><surname>Seydi</surname><given-names>M.</given-names></name><name><surname>Eholie</surname><given-names>S.P.</given-names></name><name><surname>Mills</surname><given-names>E.J.</given-names></name><name><surname>Kallay</surname><given-names>O.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Nachega</surname><given-names>J.B.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings</article-title><source>Am. J. Trop. Med. Hyg.</source><volume>102</volume><year>2020</year><fpage>1184</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0290</pub-id><pub-id pub-id-type="pmid">32323646</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>C.</given-names></name><name><surname>Rolain</surname><given-names>J.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</article-title><source>Int. J. Antimicrob. Agents</source><volume>55</volume><issue>5</issue><year>2020</year><fpage>105938</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105938</pub-id><pub-id pub-id-type="pmid">32171740</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Di Trani</surname><given-names>L.</given-names></name><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Campitelli</surname><given-names>L.</given-names></name><name><surname>Norelli</surname><given-names>S.</given-names></name><name><surname>Puzelli</surname><given-names>S.</given-names></name><name><surname>D'Ostilio</surname><given-names>D.</given-names></name><name><surname>Vignolo</surname><given-names>E.</given-names></name><name><surname>Donatelli</surname><given-names>I.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name></person-group><article-title>Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses</article-title><source>Virol. J.</source><volume>4</volume><issue>1</issue><year>2007</year><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-4-39</pub-id><pub-id pub-id-type="pmid">17477867</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Chatre</surname><given-names>C.</given-names></name><name><surname>Roubille</surname><given-names>F.</given-names></name><name><surname>Vernhet</surname><given-names>H.</given-names></name><name><surname>Jorgensen</surname><given-names>C.</given-names></name><name><surname>Pers</surname><given-names>Y.M.</given-names></name></person-group><article-title>Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature</article-title><source>Drug Saf.</source><volume>41</volume><issue>10</issue><year>2018</year><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1007/s40264-018-0689-4</pub-id><pub-id pub-id-type="pmid">29858838</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discovery</source><volume>6</volume><year>2020</year><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Current status of potential therapeutic candidates for the COVID-19 crisis</article-title><source>Brain Behav. Immun.</source><volume>87</volume><year>2020</year><fpage>59</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.04.046</pub-id><pub-id pub-id-type="pmid">32334062</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Geleris</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Platt</surname><given-names>J.</given-names></name><name><surname>Zucker</surname><given-names>J.</given-names></name><name><surname>Baldwin</surname><given-names>M.</given-names></name><name><surname>Hripcsak</surname><given-names>G.</given-names></name><name><surname>Labella</surname><given-names>A.</given-names></name><name><surname>Manson</surname><given-names>D.K.</given-names></name><name><surname>Kubin</surname><given-names>C.</given-names></name><name><surname>Barr</surname><given-names>R.G.</given-names></name><name><surname>Sobieszczyk</surname><given-names>M.E.</given-names></name><name><surname>Schluger</surname><given-names>N.W.</given-names></name></person-group><article-title>Observational study of hydroxychloroquine in hospitalized patients with Covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>2411</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2012410</pub-id><pub-id pub-id-type="pmid">32379955</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Garner</surname><given-names>L.V.</given-names></name><name><surname>Watkins</surname><given-names>S.P.</given-names></name><name><surname>Carter</surname><given-names>L.J.</given-names></name><name><surname>Smoot</surname><given-names>J.</given-names></name><name><surname>Gregg</surname><given-names>A.C.</given-names></name><name><surname>Daniels</surname><given-names>A.D.</given-names></name><name><surname>Jervey</surname><given-names>S.</given-names></name><name><surname>Albaiu</surname><given-names>D.</given-names></name></person-group><article-title>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases</article-title><source>ACS Cent. Sci.</source><volume>6</volume><year>2020</year><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id><pub-id pub-id-type="pmid">32226821</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>T.M.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name></person-group><article-title>Coronavirus spike proteins in viral entry and pathogenesis</article-title><source>Virology</source><volume>279</volume><issue>2</issue><year>2001</year><fpage>371</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1006/viro.2000.0757</pub-id><pub-id pub-id-type="pmid">11162792</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Kirchdoerfer</surname><given-names>R.N.</given-names></name><name><surname>Ward</surname><given-names>A.B.</given-names></name></person-group><article-title>Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors</article-title><source>Nat. Commun.</source><volume>10</volume><issue>1</issue><year>2019</year><fpage>2342</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10280-3</pub-id><comment>1-9</comment><pub-id pub-id-type="pmid">31138817</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>C.J.</given-names></name><name><surname>Tchesnokov</surname><given-names>E.P.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Porter</surname><given-names>D.P.</given-names></name><name><surname>G&#x000f6;tte</surname><given-names>M.</given-names></name></person-group><article-title>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</article-title><source>J. Biol. Chem.</source><volume>295</volume><year>2020</year><fpage>4773</fpage><lpage>4779</lpage><pub-id pub-id-type="doi">10.1074/jbc.AC120.013056</pub-id><pub-id pub-id-type="pmid">32094225</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><article-title>Natural products may interfere with SARS-CoV-2 attachment to the host cell</article-title><source>J. Biomol. Struct. Dyn.</source><issue>2020</issue><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1761881</pub-id><comment>[E-pub ahead of print]</comment></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>The nonstructural proteins directing coronavirus RNA synthesis and processing</article-title><source>Adv. Virus Res.</source><volume>96</volume><year>2016</year><fpage>59</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.008</pub-id><pub-id pub-id-type="pmid">27712628</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Wadhwani</surname><given-names>P.</given-names></name><name><surname>Mesters</surname><given-names>J.R.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs</article-title><source>Science</source><volume>300</volume><issue>5626</issue><year>2003</year><fpage>1763</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1126/science.1085658</pub-id><pub-id pub-id-type="pmid">12746549</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Khodadadi</surname><given-names>E.</given-names></name><name><surname>Maroufi</surname><given-names>P.</given-names></name><name><surname>Khodadadi</surname><given-names>E.</given-names></name><name><surname>Esposito</surname><given-names>I.</given-names></name><name><surname>Ganbarov</surname><given-names>K.</given-names></name><name><surname>Espsoito</surname><given-names>S.</given-names></name><name><surname>Yousefi</surname><given-names>M.</given-names></name><name><surname>Zeinalzadeh</surname><given-names>E.</given-names></name><name><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)</article-title><source>Microb. Pathog.</source><volume>146</volume><year>2020</year><fpage>104241</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020</pub-id><pub-id pub-id-type="pmid">32387389</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Stower</surname><given-names>H.</given-names></name></person-group><article-title>Lopinavir&#x02013;ritonavir in severe COVID-19</article-title><source>Nat. Med.</source><volume>26</volume><issue>4</issue><year>2020</year><pub-id pub-id-type="doi">10.1038/s41591-020-0849-9</pub-id><comment>465-465</comment></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>D.L.</given-names></name><name><surname>Sternberg</surname><given-names>A.</given-names></name><name><surname>Stange</surname><given-names>U.</given-names></name><name><surname>Laufer</surname><given-names>S.</given-names></name><name><surname>Naujokat</surname><given-names>C.</given-names></name></person-group><article-title>Candidate drugs against SARS-CoV-2 and COVID-19</article-title><source>Pharmacol. Res.</source><volume>157</volume><year>2020</year><fpage>104859</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104859</pub-id><pub-id pub-id-type="pmid">32360480</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Kuo</surname><given-names>H.D.</given-names></name><name><surname>Shannar</surname><given-names>A.</given-names></name><name><surname>Peter</surname><given-names>R.</given-names></name><name><surname>Chou</surname><given-names>P.J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Hudlikar</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Poiani</surname><given-names>G.J.</given-names></name><name><surname>Amorosa</surname><given-names>L.</given-names></name><name><surname>Brunetti</surname><given-names>L.</given-names></name><name><surname>Kong</surname><given-names>A.N.</given-names></name></person-group><article-title>An update on current therapeutic drugs treating COVID-19</article-title><source>Current Pharmacology Reports</source><volume>2020</volume><year>2020</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s40495-020-00216-7</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Mukherjee</surname><given-names>R.</given-names></name><name><surname>Grewe</surname><given-names>D.</given-names></name><name><surname>Bojkova</surname><given-names>D.</given-names></name><name><surname>Baek</surname><given-names>K.</given-names></name><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Schulz</surname><given-names>L.</given-names></name><name><surname>Widera</surname><given-names>M.</given-names></name><name><surname>Mehdipour</surname><given-names>A.R.</given-names></name><name><surname>Tascher</surname><given-names>G.</given-names></name><name><surname>Geurink</surname><given-names>P.P.</given-names></name><name><surname>Wilhelm</surname><given-names>A.</given-names></name><name><surname>van der Heden van Noort</surname><given-names>G.J.</given-names></name><name><surname>Ovaa</surname><given-names>H.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name><name><surname>Knobeloch</surname><given-names>K.P.</given-names></name><name><surname>Rajalingam</surname><given-names>K.</given-names></name><name><surname>Schulman</surname><given-names>B.A.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Hummer</surname><given-names>G.</given-names></name><name><surname>Ciesek</surname><given-names>S.</given-names></name><name><surname>Dikic</surname><given-names>I.</given-names></name></person-group><article-title>Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity</article-title><source>Research Square</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2601-5</pub-id><comment>2020, (Pre-print)</comment></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Barretto</surname><given-names>N.</given-names></name><name><surname>Jukneliene</surname><given-names>D.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity</article-title><source>J. Virol.</source><volume>79</volume><issue>24</issue><year>2005</year><fpage>15189</fpage><lpage>15198</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.24.15189-15198.2005</pub-id><pub-id pub-id-type="pmid">16306590</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>D.P.</given-names></name><name><surname>Van Krieken</surname><given-names>R.</given-names></name><name><surname>Carlos</surname><given-names>A.J.</given-names></name><name><surname>Lee</surname><given-names>A.S.</given-names></name></person-group><article-title>The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection</article-title><source>J. Infect.</source><volume>81</volume><issue>3</issue><year>2020</year><fpage>452</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.017</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Pan</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Peng</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Tao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)</article-title><source>J. Biol. Chem.</source><volume>291</volume><issue>17</issue><year>2016</year><fpage>9218</fpage><lpage>9232</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.716100</pub-id><pub-id pub-id-type="pmid">26953343</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>M.D.</given-names></name><name><surname>Ha</surname><given-names>S.D.</given-names></name><name><surname>Haeryfar</surname><given-names>S.M.M.</given-names></name><name><surname>Barr</surname><given-names>S.D.</given-names></name><name><surname>Kim</surname><given-names>S.O.</given-names></name></person-group><article-title>Cathepsin B plays a key role in optimal production of the influenza A virus</article-title><source>Journal of Virology and Antiviral Research</source><year>2018</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.4172/2324-8955.1000178</pub-id><comment>2018</comment><pub-id pub-id-type="pmid">29349092</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Zhuang</surname><given-names>M.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name></person-group><article-title>Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted</article-title><source>J. Virol.</source><volume>81</volume><issue>16</issue><year>2007</year><fpage>8722</fpage><lpage>8729</lpage><pub-id pub-id-type="doi">10.1128/JVI.00253-07</pub-id><pub-id pub-id-type="pmid">17522231</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway</article-title><source>Cell Res.</source><volume>18</volume><issue>2</issue><year>2008</year><fpage>290</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.15</pub-id><pub-id pub-id-type="pmid">18227861</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Stancioiu</surname><given-names>F.</given-names></name><name><surname>Papadakis</surname><given-names>G.Z.</given-names></name><name><surname>Kteniadakis</surname><given-names>S.</given-names></name><name><surname>Izotov</surname><given-names>B.N.</given-names></name><name><surname>Coleman</surname><given-names>M.D.</given-names></name><name><surname>Spandidos</surname><given-names>D.A.</given-names></name><name><surname>Tsatsakis</surname><given-names>A.</given-names></name></person-group><article-title>A dissection of SARS CoV2 with clinical implications</article-title><source>Int. J. Mol. Med.</source><volume>46</volume><issue>2</issue><year>2020</year><fpage>489</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2020.4636</pub-id><pub-id pub-id-type="pmid">32626922</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Shi</surname><given-names>G.P.</given-names></name></person-group><article-title>Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients</article-title><source>Pharmacol. Ther.</source><volume>213</volume><year>2020</year><fpage>107587</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107587</pub-id><pub-id pub-id-type="pmid">32470470</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="book" id="sref84"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>Z.</given-names></name><name><surname>Karatas</surname><given-names>Y.</given-names></name><name><surname>Ceylan</surname><given-names>A.F.</given-names></name><name><surname>Rahman</surname><given-names>H.</given-names></name></person-group><chapter-title>COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts</chapter-title><year>2020</year><publisher-name>Le Pharmacien Hospitalier et Clinicien</publisher-name><pub-id pub-id-type="doi">10.1016/j.phclin.2020.06.003</pub-id><comment>2020, [E-pub ahead of print]</comment></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Islam</surname><given-names>M.S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective</article-title><source>Int. J. Biol. Sci.</source><volume>16</volume><issue>10</issue><year>2020</year><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.7150/ijbs.45538</pub-id><pub-id pub-id-type="pmid">32226288</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Mirzaie</surname><given-names>A.</given-names></name><name><surname>Halaji</surname><given-names>M.</given-names></name><name><surname>Dehkordi</surname><given-names>F.S.</given-names></name><name><surname>Ranjbar</surname><given-names>R.</given-names></name><name><surname>Noorbazargand</surname><given-names>H.</given-names></name></person-group><article-title>A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19)</article-title><source>Compl. Ther. Clin. Pract.</source><volume>40</volume><year>2020</year><fpage>101214</fpage><pub-id pub-id-type="doi">10.1016/j.ctcp.2020.101214</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Khaerunnisa</surname><given-names>S.</given-names></name><name><surname>Kurniawan</surname><given-names>H.</given-names></name><name><surname>Awaluddin</surname><given-names>R.</given-names></name><name><surname>Suhartati</surname><given-names>S.</given-names></name><name><surname>Soetjipto</surname><given-names>S.</given-names></name></person-group><article-title>Potential Inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study</article-title><source>Preprints</source><year>2020</year><pub-id pub-id-type="doi">10.20944/preprints202003.0226.v1</pub-id><comment>2020, 2020030226</comment></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Ganjhu</surname><given-names>R.K.</given-names></name><name><surname>Mudgal</surname><given-names>P.P.</given-names></name><name><surname>Maity</surname><given-names>H.</given-names></name><name><surname>Dowarha</surname><given-names>D.</given-names></name><name><surname>Devadiga</surname><given-names>S.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name><name><surname>Arunkumar</surname><given-names>G.</given-names></name></person-group><article-title>Herbal plants and plant preparations as remedial approach for viral diseases</article-title><source>Virusdisease</source><volume>26</volume><issue>4</issue><year>2015</year><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s13337-015-0276-6</pub-id><pub-id pub-id-type="pmid">26645032</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Meenakshisundaram</surname><given-names>S.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name></person-group><article-title>Recent discovery and development of inhibitors targeting coronaviruses</article-title><source>Drug Discov. Today</source><volume>25</volume><issue>4</issue><year>2020</year><fpage>668</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.01.015</pub-id><pub-id pub-id-type="pmid">32006468</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>K.</given-names></name><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>M.</given-names></name><name><surname>Zuo</surname><given-names>G.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>D.</given-names></name><name><surname>Nie</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells</article-title><source>J. Virol.</source><volume>78</volume><issue>20</issue><year>2004</year><fpage>11334</fpage><lpage>11339</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.20.11334-11339.2004</pub-id><pub-id pub-id-type="pmid">15452254</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Chin</surname><given-names>Y.W.</given-names></name><name><surname>Jee</surname><given-names>J.G.</given-names></name><name><surname>Keum</surname><given-names>Y.S.</given-names></name><name><surname>Jeong</surname><given-names>Y.J.</given-names></name></person-group><article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title><source>Bioorg. Med. Chem. Lett</source><volume>22</volume><issue>12</issue><year>2012</year><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id><pub-id pub-id-type="pmid">22578462</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>P.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Ling</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Saitoh</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group><article-title>Procyanidins and butanol extract of Cinnamomi cortex inhibit SARS-CoV infection</article-title><source>Antivir. Res.</source><volume>82</volume><issue>1</issue><year>2009</year><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2009.02.001</pub-id><pub-id pub-id-type="pmid">19428598</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>Y.B.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Nguyen</surname><given-names>T.T.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name><name><surname>Chang</surname><given-names>J.S.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Rho</surname><given-names>M.C.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name></person-group><article-title>Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition</article-title><source>Bioorg. Med. Chem.</source><volume>18</volume><issue>22</issue><year>2010</year><fpage>7940</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id><pub-id pub-id-type="pmid">20934345</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Seo</surname><given-names>K.H.</given-names></name><name><surname>Curtis-Long</surname><given-names>M.J.</given-names></name><name><surname>Oh</surname><given-names>K.Y.</given-names></name><name><surname>Oh</surname><given-names>J.W.</given-names></name><name><surname>Cho</surname><given-names>J.K.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name></person-group><article-title>Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia</article-title><source>J. Enzym. Inhib. Med. Chem.</source><volume>29</volume><issue>1</issue><year>2014</year><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3109/14756366.2012.753591</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J.K.</given-names></name><name><surname>Curtis-Long</surname><given-names>M.J.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Ryu</surname><given-names>H.W.</given-names></name><name><surname>Yuk</surname><given-names>H.J.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name></person-group><article-title>Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa</article-title><source>Bioorg. Med. Chem.</source><volume>21</volume><issue>11</issue><year>2013</year><fpage>3051</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.03.027</pub-id><pub-id pub-id-type="pmid">23623680</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.W.</given-names></name><name><surname>Tsai</surname><given-names>F.J.</given-names></name><name><surname>Tsai</surname><given-names>C.H.</given-names></name><name><surname>Lai</surname><given-names>C.C.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Ho</surname><given-names>T.Y.</given-names></name><name><surname>Hsieh</surname><given-names>C.C.</given-names></name><name><surname>Chao</surname><given-names>P.D.</given-names></name></person-group><article-title>Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds</article-title><source>Antivir. Res.</source><volume>68</volume><issue>1</issue><year>2005</year><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.07.002</pub-id><pub-id pub-id-type="pmid">16115693</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Yuk</surname><given-names>H.J.</given-names></name><name><surname>Ryu</surname><given-names>H.W.</given-names></name><name><surname>Lim</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>K.S.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name></person-group><article-title>Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors</article-title><source>J. Enzym. Inhib. Med. Chem.</source><volume>32</volume><issue>1</issue><year>2017</year><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1080/14756366.2016.1265519</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.N.</given-names></name><name><surname>Lin</surname><given-names>C.P.</given-names></name><name><surname>Huang</surname><given-names>K.K.</given-names></name><name><surname>Chen</surname><given-names>W.C.</given-names></name><name><surname>Hsieh</surname><given-names>H.P.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Hsu</surname><given-names>J.T.</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3'-digallate (TF3)</article-title><source>Evid. base Compl. Alternative Med.</source><volume>2</volume><issue>2</issue><year>2005</year><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kwon</surname><given-names>J.M.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava</article-title><source>Bioorg. Med. Chem.</source><volume>21</volume><issue>13</issue><year>2013</year><fpage>3730</fpage><lpage>3737</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.026</pub-id><pub-id pub-id-type="pmid">23647823</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.H.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Curtis-Long</surname><given-names>M.J.</given-names></name><name><surname>Yuk</surname><given-names>H.J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhuang</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name><name><surname>Jeon</surname><given-names>K.S.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name></person-group><article-title>Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits</article-title><source>Biol. Pharm. Bull.</source><volume>37</volume><issue>6</issue><year>2014</year><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1248/bpb.b14-00026</pub-id><pub-id pub-id-type="pmid">24882413</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y.C.</given-names></name><name><surname>Wang</surname><given-names>L.T.</given-names></name><name><surname>Khalil</surname><given-names>A.T.</given-names></name><name><surname>Chiang</surname><given-names>L.C.</given-names></name><name><surname>Cheng</surname><given-names>P.W.</given-names></name></person-group><article-title>Bioactive pyranoxanthones from the roots of Calophyllum blancoi</article-title><source>Chem. Pharm. Bull.</source><volume>53</volume><issue>2</issue><year>2005</year><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1248/cpb.53.244</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.Y.</given-names></name><name><surname>Wu</surname><given-names>S.L.</given-names></name><name><surname>Chen</surname><given-names>J.C.</given-names></name><name><surname>Li</surname><given-names>C.C.</given-names></name><name><surname>Hsiang</surname><given-names>C.Y.</given-names></name></person-group><article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title><source>Antivir. Res.</source><volume>74</volume><issue>2</issue><year>2007</year><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id><pub-id pub-id-type="pmid">16730806</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Loizzo</surname><given-names>M.R.</given-names></name><name><surname>Saab</surname><given-names>A.M.</given-names></name><name><surname>Tundis</surname><given-names>R.</given-names></name><name><surname>Statti</surname><given-names>G.A.</given-names></name><name><surname>Menichini</surname><given-names>F.</given-names></name><name><surname>Lampronti</surname><given-names>I.</given-names></name><name><surname>Gambari</surname><given-names>R.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species</article-title><source>Chem. Biodivers.</source><volume>5</volume><issue>3</issue><year>2008</year><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200890045</pub-id><pub-id pub-id-type="pmid">18357554</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases</article-title><source>Bioorg. Med. Chem.</source><volume>20</volume><issue>19</issue><year>2012</year><fpage>5928</fpage><lpage>5935</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.07.038</pub-id><pub-id pub-id-type="pmid">22884354</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Jung</surname><given-names>Y.S.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Anti-SARS coronavirus agents: a patent review (2008&#x02013;present)</article-title><source>Expert Opin. Ther. Pat.</source><volume>23</volume><issue>10</issue><year>2013</year><fpage>1337</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1517/13543776.2013.823159</pub-id><pub-id pub-id-type="pmid">23905913</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>F.R.</given-names></name><name><surname>Yen</surname><given-names>C.T.</given-names></name><name><surname>Ei-Shazly</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>W.H.</given-names></name><name><surname>Yen</surname><given-names>M.H.</given-names></name><name><surname>Lin</surname><given-names>K.H.</given-names></name><name><surname>Wu</surname><given-names>Y.C.</given-names></name></person-group><article-title>Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia</article-title><source>Natural Product Communications</source><volume>7</volume><issue>11</issue><year>2012</year><fpage>1415</fpage><lpage>1417</lpage><comment>2012</comment><pub-id pub-id-type="pmid">23285797</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Orhan</surname><given-names>I.E.</given-names></name><name><surname>Senol Deniz</surname><given-names>F.S.</given-names></name></person-group><article-title>Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2?</article-title><source>Natural Products and Bioprospecting</source><volume>10</volume><issue>4</issue><year>2020</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s13659-020-00250-4</pub-id><pub-id pub-id-type="pmid">32016770</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>Y.C.</given-names></name><name><surname>Lee</surname><given-names>C.L.</given-names></name><name><surname>Yen</surname><given-names>H.R.</given-names></name><name><surname>Chang</surname><given-names>Y.S.</given-names></name><name><surname>Lin</surname><given-names>Y.P.</given-names></name><name><surname>Huang</surname><given-names>S.H.</given-names></name><name><surname>Lin</surname><given-names>C.W.</given-names></name></person-group><article-title>Antiviral action of Tryptanthrin isolated from Strobilanthes cusia leaf against human coronavirus NL63</article-title><source>Biomolecules</source><volume>10</volume><issue>3</issue><year>2020</year><fpage>366</fpage><pub-id pub-id-type="doi">10.3390/biom10030366</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.E.</given-names></name><name><surname>Min</surname><given-names>J.S.</given-names></name><name><surname>Jang</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Shin</surname><given-names>Y.S.</given-names></name><name><surname>Song</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>H.R.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>Y.H.</given-names></name><name><surname>Kwon</surname><given-names>S.</given-names></name></person-group><article-title>Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells</article-title><source>Biomolecules</source><volume>9</volume><issue>11</issue><year>2019</year><fpage>696</fpage><pub-id pub-id-type="doi">10.3390/biom9110696</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>P.W.</given-names></name><name><surname>Ng</surname><given-names>L.T.</given-names></name><name><surname>Chiang</surname><given-names>L.C.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name></person-group><article-title>Antiviral effects of saikosaponins on human coronavirus 229E in vitro</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><volume>33</volume><issue>7</issue><year>2006</year><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2006.04415.x</pub-id><pub-id pub-id-type="pmid">16789928</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>C.</given-names></name><name><surname>Schulte</surname><given-names>F.W.</given-names></name><name><surname>Lange-Gr&#x000fc;nweller</surname><given-names>K.</given-names></name><name><surname>Obermann</surname><given-names>W.</given-names></name><name><surname>Madhugiri</surname><given-names>R.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Hartmann</surname><given-names>R.K.</given-names></name><name><surname>Gr&#x000fc;nweller</surname><given-names>A.</given-names></name></person-group><article-title>Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona-and picornaviruses</article-title><source>Antivir. Res.</source><volume>150</volume><year>2018</year><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.12.010</pub-id><pub-id pub-id-type="pmid">29258862</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Ko</surname><given-names>J.A.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>C.Y.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV</article-title><source>J. Enzym. Inhib. Med. Chem.</source><volume>31</volume><issue>1</issue><year>2016</year><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3109/14756366.2014.1003215</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol. Pharm. Bull.</source><volume>35</volume><issue>11</issue><year>2012</year><fpage>2036</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1248/bpb.b12-00623</pub-id><pub-id pub-id-type="pmid">22971649</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Kumaki</surname><given-names>Y.</given-names></name><name><surname>Wandersee</surname><given-names>M.K.</given-names></name><name><surname>Smith</surname><given-names>A.J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Nelson</surname><given-names>N.M.</given-names></name><name><surname>Bailey</surname><given-names>K.W.</given-names></name><name><surname>Vest</surname><given-names>Z.G.</given-names></name><name><surname>Li</surname><given-names>J.K.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name></person-group><article-title>Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin</article-title><source>Antivir. Res.</source><volume>90</volume><issue>1</issue><year>2011</year><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.02.003</pub-id><pub-id pub-id-type="pmid">21338626</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>O'Keefe</surname><given-names>B.R.</given-names></name><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Barnett</surname><given-names>B.W.</given-names></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.L.</given-names></name><name><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae</article-title><source>J. Virol.</source><volume>84</volume><issue>5</issue><year>2020</year><fpage>2511</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1128/JVI.02322-09</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Karak</surname><given-names>P.</given-names></name></person-group><article-title>Biological activities of flavonoids: an overview</article-title><source>Int. J. Pharmaceut. Sci. Res.</source><volume>10</volume><issue>4</issue><year>2019</year><fpage>1567</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.13040/IJPSR.0975-8232.10(4)</pub-id><comment>1567-74</comment></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3CL protease by flavonoids</article-title><source>J. Enzym. Inhib. Med. Chem.</source><volume>35</volume><issue>1</issue><year>2020</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1080/14756366.2019.1690480</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Kaleem</surname><given-names>M.</given-names></name><name><surname>Ahmed</surname><given-names>Z.</given-names></name><name><surname>Shafiq</surname><given-names>H.</given-names></name></person-group><article-title>Therapeutic potential of flavonoids and their mechanism of action against microbial and viral infections&#x02014;a review</article-title><source>Food Res. Int.</source><volume>77</volume><issue>2</issue><year>2015</year><fpage>221</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2015.06.021</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A.</given-names></name><name><surname>Kalra</surname><given-names>S.</given-names></name></person-group><article-title>Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids</article-title><source>Research Square</source><year>2020</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.21203/rs.3.rs-34497/v1</pub-id><comment>2020</comment></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Ngwa</surname><given-names>W.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Lyerly</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>R.</given-names></name><name><surname>Reid</surname><given-names>T.E.</given-names></name><name><surname>Lowe</surname><given-names>H.</given-names></name><name><surname>Toyang</surname><given-names>N.</given-names></name></person-group><article-title>Potential of flavonoid-inspired phytomedicines against COVID-19</article-title><source>Molecules</source><volume>25</volume><issue>11</issue><year>2020</year><fpage>2707</fpage><pub-id pub-id-type="doi">10.3390/molecules25112707</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Laskin</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>J.S.</given-names></name><name><surname>Laskin</surname><given-names>J.</given-names></name></person-group><article-title>Molecular characterization of nitrogen-containing organic compounds in biomass burning aerosols using high-resolution mass spectrometry</article-title><source>Environ. Sci. Technol.</source><volume>43</volume><issue>10</issue><year>2009</year><fpage>3764</fpage><lpage>3771</lpage><pub-id pub-id-type="doi">10.1021/es803456n</pub-id><pub-id pub-id-type="pmid">19544885</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Currens</surname><given-names>M.J.</given-names></name><name><surname>Gulakowski</surname><given-names>R.J.</given-names></name><name><surname>Buckheit</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name><surname>Lackman-Smith</surname><given-names>C.</given-names></name><name><surname>Hallock</surname><given-names>Y.F.</given-names></name><name><surname>Boyd</surname><given-names>M.R.</given-names></name></person-group><article-title>Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms</article-title><source>Antimicrob. Agents Chemother.</source><volume>39</volume><year>1995</year><fpage>484</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1128/aac.39.2.484</pub-id><pub-id pub-id-type="pmid">7537029</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Wink</surname><given-names>M.</given-names></name></person-group><article-title>Potential of DNA intercalating alkaloids and other plant secondary metabolites against SARS-CoV-2 causing COVID-19</article-title><source>Diversity</source><volume>12</volume><issue>5</issue><year>2020</year><fpage>175</fpage><pub-id pub-id-type="doi">10.3390/d12050175</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Jahan</surname><given-names>I.</given-names></name><name><surname>Onay</surname><given-names>A.</given-names></name></person-group><article-title>Potentials of plant-based substance to inhabit and probable cure for the COVID-19</article-title><source>Turk. J. Biol.</source><volume>44</volume><issue>3</issue><year>2020</year><fpage>228</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.3906/biy-2005-114</pub-id><pub-id pub-id-type="pmid">32595359</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="other" id="sref125"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>A.K.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Misra</surname><given-names>N.</given-names></name></person-group><article-title>On the inhibition of COVID-19 protease by Indian herbal plants: an in silico investigation</article-title><comment>arXiv (preprint) arXiv: 2004.03411 (2020)</comment><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2004.03411v1" id="intref0025">https://arxiv.org/abs/2004.03411v1</ext-link><year>2020</year></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Bleasel</surname><given-names>M.D.</given-names></name><name><surname>Peterson</surname><given-names>G.M.</given-names></name></person-group><article-title>Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses</article-title><source>Pharmaceuticals</source><volume>13</volume><issue>3</issue><year>2020</year><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/ph13030051</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="book" id="sref127"><person-group person-group-type="author"><name><surname>Vermerris</surname><given-names>W.</given-names></name><name><surname>Nicholson</surname><given-names>R.</given-names></name></person-group><chapter-title>Phenolic Compound Biochemistry</chapter-title><year>2007</year><publisher-name>Springer Science &#x00026; Business Media</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4020-5164-7</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y.Z.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Xing</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>Q.</given-names></name><name><surname>Corke</surname><given-names>H.</given-names></name></person-group><article-title>Structure&#x02013;radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants</article-title><source>Life Sci.</source><volume>78</volume><issue>25</issue><year>2006</year><fpage>2872</fpage><lpage>2888</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2005.11.004</pub-id><pub-id pub-id-type="pmid">16325868</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Manivannan</surname><given-names>R.</given-names></name><name><surname>Punniyamoorthy</surname><given-names>A.</given-names></name><name><surname>Tamilselvan</surname><given-names>C.</given-names></name></person-group><article-title>Plant secondary metabolites of antiviral properties a rich medicinal source for drug discovery: a mini review</article-title><source>J. Drug Deliv. Therapeut.</source><volume>9</volume><issue>5</issue><year>2019</year><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.22270/jddt.v9i5.3471</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Rebensburg</surname><given-names>S.</given-names></name><name><surname>Helfer</surname><given-names>M.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Koppensteiner</surname><given-names>H.</given-names></name><name><surname>Eberle</surname><given-names>J.</given-names></name><name><surname>Schindler</surname><given-names>M.</given-names></name><name><surname>G&#x000fc;rtler</surname><given-names>L.</given-names></name><name><surname>Brack-Werner</surname><given-names>R.</given-names></name></person-group><article-title>Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>20394</fpage><pub-id pub-id-type="doi">10.1038/srep20394</pub-id><pub-id pub-id-type="pmid">26833261</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Annunziata</surname><given-names>G.</given-names></name><name><surname>Sanduzzi Zamparelli</surname><given-names>M.</given-names></name><name><surname>Santoro</surname><given-names>C.</given-names></name><name><surname>Ciampaglia</surname><given-names>R.</given-names></name><name><surname>Stornaiuolo</surname><given-names>M.</given-names></name><name><surname>Tenore</surname><given-names>G.C.</given-names></name><name><surname>Sanduzzi</surname><given-names>A.</given-names></name><name><surname>Novellino</surname><given-names>E.</given-names></name></person-group><article-title>May polyphenols have a role against coronavirus infection? An overview of in vitro evidence</article-title><source>Front. Med.</source><volume>7</volume><year>2020</year><fpage>240</fpage><pub-id pub-id-type="doi">10.3389/fmed.2020.00240</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Edris</surname><given-names>A.E.</given-names></name></person-group><article-title>Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review</article-title><source>Phytother Res.</source><volume>21</volume><issue>4</issue><year>2007</year><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1002/ptr.2072</pub-id><pub-id pub-id-type="pmid">17199238</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Kapoor</surname><given-names>I.P.S.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>de Heluani</surname><given-names>C.S.</given-names></name><name><surname>de Lampasona</surname><given-names>M.P.</given-names></name><name><surname>Catalan</surname><given-names>C.A.N.</given-names></name></person-group><article-title>Chemistry, antioxidant and antimicrobial investigations on essential oil and oleoresins of Zingiber officinale</article-title><source>Food Chem. Toxicol.</source><volume>46</volume><issue>10</issue><year>2008</year><fpage>3295</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2008.07.017</pub-id><pub-id pub-id-type="pmid">18706468</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Nadjib</surname><given-names>B.M.</given-names></name></person-group><article-title>Effective antiviral activity of essential oils and their characteristic terpenes against coronaviruses: an update</article-title><source>Journal of Pharmacology &#x00026; Clinical Toxicology</source><volume>8</volume><issue>1</issue><year>2020</year><fpage>1138</fpage></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.D.</given-names></name><name><surname>Kaur</surname><given-names>I.</given-names></name></person-group><article-title>Eucalyptol (1, 8 cineole) from eucalyptus essential oil a potential inhibitor of COVID 19 corona virus infection by molecular docking studies</article-title><source>Preprints</source><year>2020</year><pub-id pub-id-type="doi">10.20944/preprints202003.0455.v1</pub-id><comment>2020, 2020030455</comment></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="book" id="sref136"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>C.F.</given-names></name><name><surname>Hammer</surname><given-names>K.A.</given-names></name></person-group><chapter-title>Chemistry and bioactivity of essential oils</chapter-title><person-group person-group-type="editor"><name><surname>Thormar</surname><given-names>H.</given-names></name></person-group><source>Lipids and Essential Oils as Antimicrobial Agents</source><year>2011</year><publisher-name>John Wiley &#x00026; Sons Ltd</publisher-name><publisher-loc>Chichester</publisher-loc><fpage>203</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1002/9780470976623.ch9</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Meneses</surname><given-names>R.</given-names></name><name><surname>Ocazionez</surname><given-names>R.E.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>J.R.</given-names></name><name><surname>Stashenko</surname><given-names>E.E.</given-names></name></person-group><article-title>Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro</article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><volume>8</volume><issue>1</issue><year>2019</year><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-8-8</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.T.</given-names></name><name><surname>Ather</surname><given-names>A.</given-names></name><name><surname>Thompson</surname><given-names>K.D.</given-names></name><name><surname>Gambari</surname><given-names>R.</given-names></name></person-group><article-title>Extracts and molecules from medicinal plants against herpes simplex viruses</article-title><source>Antivir. Res.</source><volume>67</volume><issue>2</issue><year>2005</year><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.05.002</pub-id><pub-id pub-id-type="pmid">16040137</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name><surname>Govindarajan</surname><given-names>M.</given-names></name><name><surname>Rajeswary</surname><given-names>M.</given-names></name><name><surname>Hoti</surname><given-names>S.L.</given-names></name><name><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name><surname>Benelli</surname><given-names>G.</given-names></name></person-group><article-title>Eugenol, &#x003b1;-pinene and &#x003b2;-caryophyllene from Plectranthus barbatus essential oil as eco-friendly larvicides against malaria, dengue and Japanese encephalitis mosquito vectors</article-title><source>Parasitol. Res.</source><volume>115</volume><issue>2</issue><year>2016</year><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1007/s00436-015-4809-0</pub-id><pub-id pub-id-type="pmid">26518773</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Swamy</surname><given-names>M.K.</given-names></name><name><surname>Akhtar</surname><given-names>M.S.</given-names></name><name><surname>Sinniah</surname><given-names>U.R.</given-names></name></person-group><article-title>Antimicrobial properties of plant essential oils against human pathogens and their mode of action: an updated review</article-title><source>Evid. base Compl. Alternative Med.</source><year>2016</year><fpage>3012462</fpage><pub-id pub-id-type="doi">10.1155/2016/3012462</pub-id><comment>2016</comment></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>Z.A.</given-names></name><name><surname>Iqbal</surname><given-names>A.</given-names></name><name><surname>Shahzad</surname><given-names>S.A.</given-names></name></person-group><article-title>Synthetic approaches toward stilbenes and their related structures</article-title><source>Mol. Divers.</source><volume>21</volume><issue>2</issue><year>2017</year><fpage>483</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1007/s11030-017-9736-9</pub-id><pub-id pub-id-type="pmid">28429182</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Reinisalo</surname><given-names>M.</given-names></name><name><surname>Kaelung</surname><given-names>A.</given-names></name><name><surname>Koskela</surname><given-names>A.</given-names></name><name><surname>Kaarniranta</surname><given-names>K.</given-names></name><name><surname>Karjalainen</surname><given-names>R.O.</given-names></name></person-group><article-title>Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases</article-title><source>Oxidative Medicine and Cellular Longevity</source><year>2015</year><fpage>340520</fpage><pub-id pub-id-type="doi">10.1155/2015/340520</pub-id><comment>2015</comment><pub-id pub-id-type="pmid">26180583</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>P.</given-names></name><name><surname>Rane</surname><given-names>J.S.</given-names></name><name><surname>Chatterjee</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>R.</given-names></name><name><surname>Prakash</surname><given-names>A.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name></person-group><article-title>Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development</article-title><source>J. Biomol. Struct. Dyn.</source><issue>2020</issue><year>2020</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1796811</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>Wahedi</surname><given-names>H.M.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Abbasi</surname><given-names>S.W.</given-names></name></person-group><article-title>Stilbene-based natural compounds as promising drug candidates against COVID-19</article-title><source>J. Biomol. Struct. Dyn.</source><volume>2020</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1762743</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.Q.</given-names></name><name><surname>Li</surname><given-names>Z.L.</given-names></name><name><surname>Zhao</surname><given-names>W.J.</given-names></name><name><surname>Wen</surname><given-names>R.X.</given-names></name><name><surname>Meng</surname><given-names>Q.W.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication</article-title><source>Eur. J. Med. Chem.</source><volume>41</volume><issue>9</issue><year>2006</year><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2006.03.024</pub-id><pub-id pub-id-type="pmid">16875760</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S.C.</given-names></name><name><surname>Ho</surname><given-names>C.T.</given-names></name><name><surname>Chuo</surname><given-names>W.H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name></person-group><article-title>Effective inhibition of MERS-CoV infection by resveratrol</article-title><source>BMC Infect. Dis.</source><volume>17</volume><issue>1</issue><year>2017</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12879-017-2253-8</pub-id><pub-id pub-id-type="pmid">28049444</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name><surname>Kren</surname><given-names>V.</given-names></name><name><surname>Mart&#x000ed;nkov&#x000e1;</surname><given-names>L.</given-names></name></person-group><article-title>Glycosides in medicine: &#x0201c;the role of glycosidic residue in biological activity.&#x0201d;</article-title><source>Curr. Med. Chem.</source><volume>8</volume><issue>11</issue><year>2001</year><fpage>1303</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.2174/0929867013372193</pub-id><pub-id pub-id-type="pmid">11562268</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="book" id="sref148"><person-group person-group-type="author"><name><surname>Emamzadeh-Yazdi</surname><given-names>S.</given-names></name></person-group><chapter-title>Antiviral, antibacterial and cytotoxic activities of South African plants containing cardiac glycosides</chapter-title><year>2013</year><publisher-name>Dissertation, University of Pretoria</publisher-name><comment>2013</comment><ext-link ext-link-type="uri" xlink:href="http://hdl.handle.net/2263/33163" id="intref0030">http://hdl.handle.net/2263/33163</ext-link></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>R.W.</given-names></name><name><surname>Lingwood</surname><given-names>C.A.</given-names></name><name><surname>Ostrowski</surname><given-names>M.A.</given-names></name><name><surname>Cabral</surname><given-names>T.</given-names></name><name><surname>Cochrane</surname><given-names>A.</given-names></name></person-group><article-title>Cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling</article-title><source>Sci. Rep.</source><volume>8</volume><issue>1</issue><year>2018</year><fpage>850</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-19298-x</pub-id><pub-id pub-id-type="pmid">29339801</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name><surname>Loregian</surname><given-names>A.</given-names></name><name><surname>Mercorelli</surname><given-names>B.</given-names></name><name><surname>Nannetti</surname><given-names>G.</given-names></name><name><surname>Compagnin</surname><given-names>C.</given-names></name><name><surname>Pal&#x000f9;</surname><given-names>G.</given-names></name></person-group><article-title>Antiviral strategies against influenza virus: towards new therapeutic approaches</article-title><source>Cell. Mol. Life Sci.</source><volume>71</volume><issue>19</issue><year>2014</year><fpage>3659</fpage><lpage>3683</lpage><pub-id pub-id-type="doi">10.1007/s00018-014-1615-2</pub-id><pub-id pub-id-type="pmid">24699705</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name><surname>Vanderlinden</surname><given-names>E.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>Emerging antiviral strategies to interfere with influenza virus entry</article-title><source>Med. Res. Rev.</source><volume>34</volume><issue>2</issue><year>2014</year><fpage>301</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1002/med.21289</pub-id><pub-id pub-id-type="pmid">23801557</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name></person-group><article-title>Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication</article-title><source>Sci. Rep.</source><volume>10</volume><issue>1</issue><year>2020</year><fpage>1897</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-58443-3</pub-id><pub-id pub-id-type="pmid">32024921</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="book" id="sref153"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>M.T.</given-names></name><name><surname>Sarkar</surname><given-names>C.</given-names></name><name><surname>El-Kersh</surname><given-names>D.M.</given-names></name><name><surname>Jamaddar</surname><given-names>S.</given-names></name><name><surname>Uddin</surname><given-names>S.J.</given-names></name><name><surname>Shilpi</surname><given-names>J.A.</given-names></name><name><surname>Mubarak</surname><given-names>M.S.</given-names></name></person-group><chapter-title>Natural products and their derivatives against coronavirus: a review of the non&#x02010;clinical and pre&#x02010;clinical data</chapter-title><year>2020</year><publisher-name>Phytotherapy Research</publisher-name><fpage>2020</fpage><pub-id pub-id-type="doi">10.1002/ptr.6700</pub-id><comment>[E-pub ahead of print]</comment></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="book" id="sref154"><person-group person-group-type="author"><name><surname>Kregiel</surname><given-names>D.</given-names></name><name><surname>Berlowska</surname><given-names>J.</given-names></name><name><surname>Witonska</surname><given-names>I.</given-names></name><name><surname>Antolak</surname><given-names>H.</given-names></name><name><surname>Proestos</surname><given-names>C.</given-names></name><name><surname>Babic</surname><given-names>M.</given-names></name><name><surname>Babic</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group><chapter-title>Saponin-based, biological-active surfactants from plants</chapter-title><person-group person-group-type="editor"><name><surname>Najjar</surname><given-names>R.</given-names></name></person-group><source>Application and Characterization of Surfactants</source><year>2017</year><publisher-name>IntechOpen</publisher-name><publisher-loc>London</publisher-loc><fpage>183</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.5772/68062</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="book" id="sref155"><person-group person-group-type="author"><name><surname>Waller</surname><given-names>G.R.</given-names></name><name><surname>Yamasaki</surname><given-names>K.</given-names></name></person-group><chapter-title>Saponins used in traditional and modern medicine</chapter-title><year>2013</year><publisher-name>Springer Science &#x00026; Business Media</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4899-1367-8</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name><surname>Roner</surname><given-names>M.R.</given-names></name><name><surname>Sprayberry</surname><given-names>J.</given-names></name><name><surname>Spinks</surname><given-names>M.</given-names></name><name><surname>Dhanji</surname><given-names>S.</given-names></name></person-group><article-title>Antiviral activity obtained from aqueous extracts of the Chilean soapbark tree (Quillaja saponaria Molina)</article-title><source>J. Gen. Virol.</source><volume>88</volume><issue>1</issue><year>2007</year><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1099/vir.0.82321-0</pub-id><pub-id pub-id-type="pmid">17170461</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>X.J.</given-names></name><name><surname>Zhang</surname><given-names>L.J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>X.Z.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>An</surname><given-names>L.K.</given-names></name><name><surname>Lui</surname><given-names>H.Y.</given-names></name></person-group><article-title>Polyphyllosides A&#x02013;F, six new spirostanol saponins from the stems and leaves of Paris polyphylla var. chinensis</article-title><source>Bioorg. Chem.</source><volume>99</volume><year>2020</year><fpage>103788</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103788</pub-id><pub-id pub-id-type="pmid">32244126</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name><surname>Amoros</surname><given-names>M.</given-names></name><name><surname>Fauconnier</surname><given-names>B.</given-names></name><name><surname>Girre</surname><given-names>R.L.</given-names></name></person-group><article-title>In vitro antiviral activity of a saponin from Anagallis arvensis, Primulaceae, against herpes simplex virus and poliovirus</article-title><source>Antivir. Res.</source><volume>8</volume><issue>1</issue><year>1987</year><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(87)90084-2</pub-id><pub-id pub-id-type="pmid">2825589</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name><surname>Bahbah</surname><given-names>E.I.</given-names></name><name><surname>Negida</surname><given-names>A.</given-names></name><name><surname>Nabet</surname><given-names>M.S.</given-names></name></person-group><article-title>Purposing saikosaponins for the treatment of COVID-19</article-title><source>Med. Hypotheses</source><volume>140</volume><year>2020</year><fpage>109782</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2020.109782</pub-id><pub-id pub-id-type="pmid">32353743</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name><surname>Buzzini</surname><given-names>P.</given-names></name><name><surname>Arapitsas</surname><given-names>P.</given-names></name><name><surname>Goretti</surname><given-names>M.</given-names></name><name><surname>Branda</surname><given-names>E.</given-names></name><name><surname>Turchetti</surname><given-names>B.</given-names></name><name><surname>Pinelli</surname><given-names>P.</given-names></name><name><surname>Ieri</surname><given-names>F.</given-names></name><name><surname>Romani</surname><given-names>A.</given-names></name></person-group><article-title>Antimicrobial and antiviral activity of hydrolysable tannins</article-title><source>Mini Rev. Med. Chem.</source><volume>8</volume><issue>12</issue><year>2008</year><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.2174/138955708786140990</pub-id><pub-id pub-id-type="pmid">18855732</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S.</given-names></name><name><surname>Chakraborty</surname><given-names>R.</given-names></name><name><surname>Sridhar</surname><given-names>C.</given-names></name><name><surname>Reddy</surname><given-names>Y.S.R.</given-names></name><name><surname>De</surname><given-names>B.</given-names></name></person-group><article-title>Free radicals, antioxidants, diseases and phytomedicines: current status and future prospect</article-title><source>Int. J. Pharmaceut. Sci. Rev. Res.</source><volume>3</volume><issue>1</issue><year>2010</year><fpage>91</fpage><lpage>100</lpage></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name><surname>Uchide</surname><given-names>N.</given-names></name><name><surname>Toyoda</surname><given-names>H.</given-names></name></person-group><article-title>Antioxidant therapy as a potential approach to severe influenza-associated complications</article-title><source>Molecules</source><volume>16</volume><issue>3</issue><year>2011</year><fpage>2032</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.3390/molecules16032032</pub-id><pub-id pub-id-type="pmid">21358592</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name><surname>Khalifa</surname><given-names>I.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Nafie</surname><given-names>M.S.</given-names></name><name><surname>Dutta</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Anti-COVID-19 effects of ten structurally different hydrolysable tannins through binding with the catalytic-closed sites of COVID-19 main protease: an in-silico approach</article-title><source>Preprints</source><year>2020</year><pub-id pub-id-type="doi">10.20944/preprints202003.0277.v1</pub-id><comment>2020, 2020030277</comment></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Wei</surname><given-names>D.Q.</given-names></name><name><surname>Du</surname><given-names>Q.S.</given-names></name><name><surname>Chou</surname><given-names>K.C.</given-names></name></person-group><article-title>Molecular modeling studies of peptide drug candidates against SARS</article-title><source>Med. Chem.</source><volume>2</volume><issue>3</issue><year>2006</year><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.2174/157340606776930736</pub-id><pub-id pub-id-type="pmid">16948478</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>R.D.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name></person-group><article-title>COVID-19 Ayurveda treatment protocol of governments of Nepal and India: a review and perspective</article-title><source>Applied Science and Technology Annals</source><volume>1</volume><issue>1</issue><year>2020</year><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.3126/asta.v1i1.30276</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>E.M.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C.E.</given-names></name></person-group><article-title>Anthraquinones as pharmacological tools and drugs</article-title><source>Med. Res. Rev.</source><volume>36</volume><issue>4</issue><year>2016</year><fpage>705</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1002/med.21391</pub-id><pub-id pub-id-type="pmid">27111664</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>J.-G.</given-names></name></person-group><article-title>Health functions and structure&#x02013;activity relationships of natural anthraquinones from plants</article-title><source>Food &#x00026; Function</source><volume>9</volume><issue>12</issue><year>2018</year><fpage>6063</fpage><lpage>6080</lpage><pub-id pub-id-type="doi">10.1039/c8fo01569d</pub-id><pub-id pub-id-type="pmid">30484455</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>Chu</surname><given-names>C.K.</given-names></name><name><surname>Babu</surname><given-names>J.R.</given-names></name><name><surname>Oswald</surname><given-names>B.J.</given-names></name><name><surname>Saalmann</surname><given-names>V.</given-names></name><name><surname>Cannon</surname><given-names>D.L.</given-names></name><name><surname>Eriksson</surname><given-names>B.F.</given-names></name><name><surname>Nasr</surname><given-names>M.</given-names></name></person-group><article-title>Anthraquinones as a new class of antiviral agents against human immunodeficiency virus</article-title><source>Antivir. Res.</source><volume>13</volume><issue>5</issue><year>1990</year><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(90)90071-e</pub-id><pub-id pub-id-type="pmid">1697740</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name><surname>Khanal</surname><given-names>P.</given-names></name><name><surname>Patil</surname><given-names>B.M.</given-names></name><name><surname>Chand</surname><given-names>J.</given-names></name><name><surname>Naaz</surname><given-names>Y.</given-names></name></person-group><article-title>Anthraquinone derivatives as an immune booster and their therapeutic option against COVID-19</article-title><source>Natural Products and Bioprospecting</source><volume>1&#x02013;11</volume><year>2020</year><pub-id pub-id-type="doi">10.1007/s13659-020-00260-2</pub-id><comment>[E-pub ahead of print]</comment></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>A.S.</given-names></name></person-group><article-title>Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: a molecular docking study</article-title><source>ChemRxiv</source><volume>2020</volume><year>2020</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.26434/chemrxiv.12245270.v1</pub-id><comment>(Pre-print)</comment></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name><surname>Naithani</surname><given-names>R.</given-names></name><name><surname>Huma</surname><given-names>L.C.</given-names></name><name><surname>Holland</surname><given-names>L.E.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name><name><surname>McCormick</surname><given-names>D.</given-names></name><name><surname>Mehta</surname><given-names>R.</given-names></name><name><surname>Moriarty</surname><given-names>R.M.</given-names></name></person-group><article-title>Antiviral activity of phytochemicals: a comprehensive review</article-title><source>Mini Rev. Med. Chem.</source><volume>8</volume><issue>11</issue><year>2008</year><fpage>1106</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.2174/138955708785909943</pub-id><pub-id pub-id-type="pmid">18855727</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name><surname>Sydiskis</surname><given-names>R.J.</given-names></name><name><surname>Owen</surname><given-names>D.G.</given-names></name><name><surname>Lohr</surname><given-names>J.L.</given-names></name><name><surname>Rosler</surname><given-names>K.H.</given-names></name><name><surname>Blomster</surname><given-names>R.N.</given-names></name></person-group><article-title>Inactivation of enveloped viruses by anthraquinones extracted from plants</article-title><source>Antimicrob. Agents Chemother.</source><volume>35</volume><issue>12</issue><year>1991</year><fpage>2463</fpage><lpage>2466</lpage><pub-id pub-id-type="doi">10.1128/aac.35.12.2463</pub-id><pub-id pub-id-type="pmid">1810179</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name><surname>Ul Qamar</surname><given-names>M.T.</given-names></name><name><surname>Alqahtani</surname><given-names>S.M.</given-names></name><name><surname>Alamri</surname><given-names>M.A.</given-names></name><name><surname>Chen</surname><given-names>L.L.</given-names></name></person-group><article-title>Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants</article-title><source>Journal of Pharmaceutical Analysis</source><volume>10</volume><issue>4</issue><year>2020</year><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><pub-id pub-id-type="pmid">32296570</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name><surname>Da Silva Antonio</surname><given-names>A.</given-names></name><name><surname>Moreira Wiedemann</surname><given-names>L.S.</given-names></name><name><surname>Veiga-Junior</surname><given-names>V.F.</given-names></name></person-group><article-title>Natural products' role against COVID-19</article-title><source>RSC Adv.</source><volume>10</volume><issue>39</issue><year>2020</year><fpage>23379</fpage><lpage>23393</lpage><pub-id pub-id-type="doi">10.1039/D0RA03774E</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>M.</given-names></name><name><surname>Latha</surname><given-names>N.</given-names></name></person-group><article-title>In silico studies reveal potential antiviral activity of phytochemicals from medicinal plants for the treatment of COVID-19 infection</article-title><source>Research Square</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.21203/rs.3.rs-22687/v1</pub-id><comment>(Pre-print)</comment></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0185">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.xml"><alt-text>Multimedia component 1</alt-text></media></supplementary-material>
</p></sec><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0190">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cbi.2021.109449" id="intref0010">https://doi.org/10.1016/j.cbi.2021.109449</ext-link>.</p></fn></fn-group></back></article>